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 Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease and is 
characterized by progressive paralysis leading to death, typically, within 3-5 years of the onset of 
symptoms. The majority of ALS cases are sporadic with no known causative agent; however, 5-
10% of ALS cases are genetically inherited and termed familial ALS (fALS). Approximately, 
15-20% of these fALS cases have been linked to mutations in the gene encoding human Cu/Zn 
superoxide dismutase (hSOD). To date, over 140 hSOD mutations have been discovered. The 
mechanisms by which mutant hSOD confers toxicity in fALS patients are still unknown. 
However, there is growing evidence that ALS is a type of protein conformational disease 
whereby cell damage or death is caused by the accumulation of protein aggregates in the cell. It 
is hypothesized that mutations destabilise hSOD and increase its propensity to aggregate. There 
is some controversy as to which hSOD species contributes to aggregation. Many believe that 
only apo or mismetallated forms of hSOD are able to aggregate. Due to the abundance of fully 
metallated or holo hSOD in the cell, we hypothesize that holo hSOD can also lead to 
aggregation. Holo dimer interface mutants A4S, A4T and I113T as well as G41D were found to 
be destabilized compared to holo pseudo wildtype (pWT) while zinc binding mutant H80R was 
shown to form fragments via an unknown mechanism. Holo dimer interface mutants A4S and 
A4T were also shown to have an increased propensity to aggregate compared to pWT, which 
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Chapter 1 General introduction 
 
1.1 Protein conformational diseases 
 
 Protein conformational diseases (PCDs) are a group of diseases that involve the 
conversion of a specific protein or proteins from a native fold to a non-native fold that eventually 
leads to the formation cytotoxic oligomers or aggregates (1). As many as forty types of PCDs 
have been discovered to date (2,3). The different proteins involved in PCDs do not share any 
similarities in primary sequence or native structure; however, they share a vital characteristic 
whereby the proteins involved have the ability to adopt certain conformational changes that 
enable the formation of insoluble aggregates (3). Protein folding is a complicated process that 
includes many opportunities for side reactions that can lead to aggregate-formation (4). The 
majority of cases of PCDs are sporadic with no known causative agents. However, a small 
portion of PCDs are associated with mutations in their associated proteins. These familial forms 
of PCDs may provide some insight to the pathogenesis of the diseases. The mutations that occur 
in the disease associated proteins tend to be dominantly inherited and are usually associated with 
earlier disease onset (5), implying that these mutations possess some characteristics that confer 
increased toxicity.  
 Like many neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s 
disease (PD), Huntington’s disease (HD) and transmissible spongiform encephalopathies (TSE), 
amyotrophic lateral sclerosis (ALS) has been proposed to be a PCD (2). However, unlike these 
diseases, ALS is not an amyloid disease. Amyloid diseases are characterised by positive Congo 
red staining with green-gold birefringence when viewed under polarized light (6-8) and amyloid 
deposits with rigid unbranched fibrils with diameters of 5-13 nm and lengths of 0.1-1.6 μm 
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(7,9,10). On the other hand, deposits found in ALS patients do not bind Congo red (11) and 
contain filamentous as well as granule-coated fibrils (12-14). 
1.2 Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease with a 
prevalence of 1.5-2.5 in 100,000 individuals per year (15). To date, no cure has been found for 
ALS and ALS treatment has only been able to slightly delay disease progression (16,17). 
Amyotrophic lateral sclerosis is also referred to as Charcot’s disease, after Jean-Martin Charcot 
who characterized the disease over 130 years ago, and more commonly as Lou Gehrig’s disease, 
after a famous American baseball player who was stricken by the disease in the late 1930s 
(18,19). Amyotrophic lateral sclerosis is a late onset disease with an average onset age of 46 
years (range 24-72) and is usually fatal within 3-5 years (range 0.3-20 years) of the onset of 
symptoms (20). Early symptoms of ALS usually are weakness in the arms and legs which 
progressively degenerates, inevitably leading to paralysis and death, usually due to respiratory 
failure. There are also cases of bulbar onset which then extends outwards. The disease selectively 
targets the motor neurons in the spinal cord, brain stem and cortex which usually leave the 
patients’ intellect unaffected.  
The majority of ALS cases have no known causative agents and are termed sporadic ALS 
(sALS). However, a small percentage of ALS cases, about 5-10%, are genetically inherited and 
termed familial ALS (fALS). In 1993, Rosen et al. discovered a genetic link between a subset of 
fALS cases and mutations in the sod1 gene (21), which codes for human Cu/Zn superoxide 
dismutase (hSOD). Since then, over 140 fALS linked hSOD mutations, representing 
approximately 20% of all fALS cases (19), have been discovered (database containing hSOD 
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mutations found at http://alsod.iop.kcl.ac.uk/Als/index.aspx). Although hSOD mutations are 
associated to a small fraction of all ALS cases, it is currently the most widely studied and major 
known cause of the disease. Mutations in sod1 have also been implicated in ~1% of sALS cases 
(22). In addition, both hSOD mutant-mediated fALS and sALS display the same symptoms and 
are clinically identical, suggesting a similar disease mechanism (20,23). By studying hSOD, it 
may be possible to elucidate the mechanism of pathogenesis and, ultimately, shed more light on 
this enigmatic disease.  
1.3 Human Cu/Zn Superoxide Dismutase 
 
 Superoxide dismutase (SOD) is an antioxidant enzyme that protects cells from the 
harmful effects of superoxide, a reactive oxygen species, and is ubiquitously found in all aerobic 
organisms (24). In eukaryotes, it is found in the cytosol, nucleus, peroxisomes and mitochondrial 
intermembrane space (19). The human Cu/Zn superoxide dismutase (hSOD) is encoded in the 
sod1 gene located on the long arm of chromosome 21, more specifically at 21q22 (25,26). It is a 
single copy gene spanning 11 kilobases and contains five exons and four introns.  
1.3.1 Structure and function 
 
 Human Cu/Zn superoxide dismutase is a very stable homodimeric enzyme. The 
homodimer is 32 kDa in size and each monomer consists of 153 amino acids. Each monomer is 
composed of an 8-stranded Greek key β-barrel. The eight β-strands are antiparallel and are joined 
by loops (27). Each monomer also contains an active site that preferentially and very tighly binds 
one Cu2+ and one Zn2+ (Figure 1.1) (28). The active site on the surface of the β-barrel and is 
enclosed by loop 4, which is the zinc binding loop that extends into the dimer interface, and loop 
7, which is the electrostatic loop. Each hSOD monomer has four cysteines; Cys-57 and Cys-146 
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form a conserved intramolecular disulfide bond while Cys-6 and Cys-111 are free cysteines (28). 
The structure of the enzyme as well as the active site residues are highly conserved (19,27). 
Figure 1.1 is a representation of the crystal structure of pseudo wildtype (pWT) hSOD (Section 
2.1.1) with the intramolecular disulfide bonds and metals shown along with a schematic 
illustrating the Greek key motif of hSOD. pWT is a C6S/C111A double mutant that removes the 












Figure 1.1 A ribbon representation of crystal structure (A) and schematic (B) of the hSOD 
dimer. (A) Prepared using MolMol (29) and PDB coordinates 1SOS (30). The eight β-strands 
are in blue while the three α-helices are in pink and yellow. Each monomer contains a Zn2+ and a 
Cu2+ ion depicted as black and orange spheres, respectively. In both figures, the intramolecular 




Both metals in hSOD are important for the structural stability of the active site. The 
copper ion is an essential cofactor in hSOD catalysis and is cyclically oxidized and reduced 
during catalysis. Human Cu/Zn superoxide dismutase catalyzes the dismutation of two 
superoxide molecules to dioxygen and hydrogen peroxide (Reactions 1-3, below) (19). The 
catalysis begins with the reduction of the cupric ion by the first molecule of superoxide to 
produce molecular oxygen (Reaction 1) (19). The second superoxide molecule then reoxidizes 
the cuprous ion to produce hydrogen peroxide (Reaction 2) (19). Superoxide dismutase is among 
the fastest enzymes known with a rate constant of ~2 x 109 M-1s-1 (31). 
               O2 - + Cu2+ZnSOD → O2 + Cu+ZnSOD   Reaction 1 
                   O2 - + 2 H+ + Cu+ZnSOD → H2O2 + Cu2+ZnSOD  Reaction 2 
Overall reaction 
                                      2O2 - + 2 H+ → O2 + H2O2    Reaction 3 
1.4 Familial ALS-associated hSOD mutations 
 
 Of the 145 sod1 gene mutations linked to ALS, at least 117 are single amino acid 
substitutions at one of 74 different residues (shown in Table 1.1) (mutation list obtained from an 
online database http://alsod.iop.kcl.ac.uk/Als/index.aspx). Other sod1 mutations include 
deletions or insertions, frameshift mutations and truncations (not indicated in Table 1.1) (19,32). 
All known sod1 mutations are dominantly inherited except for D90A which exhibits variable 
inheritance (33-35). Although mutations are scattered throughout the protein, some of the 
mutations can be categorized into two distinct groups: metal binding region (MBR) mutants and 
dimer interface mutants. Metal binding region mutants are mutations that occur at the metal 
coordinating residues as well as residues in the electrostatic and zinc loops. These affect the 
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metal binding ability of the protein, and are expected to result in lower enzymatic activity (19). 
Dimer interface mutants, on the other hand, are mutations that occur in and around the dimer 
interface and may affect the stability of the protein. To date, no clear trends have been identified 
among the different types of hSOD mutations.  However, a recent computational study has 




















Table 1.1  The amino acid sequence of hSOD along with fALS-associated substitution 
mutations. The mutations are listed in red. Boxes shaded blue indicate residues in β-strands. The 
circles above specific residues denote metal coordinating residues where the copper and zinc are 
represented by yellow and black circles, respectively (mutation list obtained from an online 
database http://alsod.iop.kcl.ac.uk/Als/index.aspx). 
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1.5 Human SOD involvement in ALS pathology  
 
Due to the role of superoxide dismutase as an antioxidant enzyme, it was initially thought 
that hSOD toxicity was due to a loss or decrease in enzymatic activity (23). However, many 
studies indicate that hSOD toxicity is caused by a toxic gain-of-function as opposed to a loss of 
function. For example, transgenic mice expressing fALS-associated hSOD mutants show ALS-
like symptoms despite having elevated hSOD activity (37). More compelling evidence against 
the loss of function theory is the fact that hSOD knockout transgenic mice do not develop motor 
neuron disease and appear to have a normal lifespan (38). Other studies showed that transgenic 
mice coexpressing endogenous mouse SOD with fALS-associated hSOD mutants still develop 
ALS-like symptoms and overexpressing wild-type hSOD with mutant hSOD either did not 
alleviate the symptoms or accelerated disease progression (39), suggesting that cytotoxicity is 
due to some intrinsic property in the hSOD mutants.  
 Despite the strong consensus for the toxic gain-of-function theory, the specific 
mechanism of pathogenesis has yet to be elucidated. The two main gain-of-toxic function 
hypotheses, which are not mutually exclusive, are: 1) oxidative damage hypothesis and 2) 
protein aggregation hypothesis. The oxidative damage hypothesis proposes that ALS-associated 
mutations reduce the specificity of the active site, increasing the probability of harmful, non-
native chemistry and the generation of free radicals. In the presence of hydrogen peroxide, 
mutant hSOD have been shown to generate hydroxyl radicals that can lead to oxidative damage 
and deactivation of the enzyme (40-42). Additionally, G93A mouse model studies found 
increased levels of oxygen radicals and oxidative damage in the spinal cords of the mice (43,44). 
HSOD can also react with peroxynitrite to produce a nitronium-like intermediate that can then 
nitrate tyrosine residues leading to protein damage (45). Elevated levels of nitrotyrosine have 
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been found in motor neurons of sALS and fALS patients (46) as well as ALS mice models 
(47,48). Despite the supporting evidence for the oxidative damage hypothesis, it is unlikely that 
it is the common factor causing ALS. This is due to the fact that these mechanisms require the 
presence of the active site copper and metal binding mutants that have decreased/no copper 
binding still lead to the disease. Additionally, a mice model with all four copper binding residues 
mutated, eliminating copper binding, nevertheless develope typical disease symptoms (49). 
The protein aggregation hypothesis proposes that fALS-associated mutations increase 
hSOD’s propensity to misfold and aggregate, and it is the aggregates that confer hSOD’s 
cytotoxic properties.  Indeed, protein misfolding and aggregation appear to be associated with 
the pathogenesis of many neurodegenerative diseases such as Alzheimer’s disease (AD), 
Parkinson’s disease (PD) and Huntington’s disease (HD) (19). Proteinaceous inclusions from 
some sALS and fALS patients (50-52), transgenic mice and cell culture models of ALS have all 
been shown to be strongly immunoreactive to hSOD antibodies (37,39,53). In cell lines where 
protein folding chaperones are co-expressed with mutant hSOD, aggregate formation is reduced 
while cell viability increases (54), implicating that aggregates play a role in cell death. It is likely 
that fALS-associated hSOD mutant pathogenesis is not exclusively caused by a single 
mechanism; however, hSOD aggregation clearly plays a role in fALS pathology.  
 
1.6 Research objective and outline 
Our lab in focused on elucidating the mechanisms whereby ALS-associated hSOD 
mutations increase the propensity of hSOD to aggregate. This thesis presents biophysical 
analyses of fALS-associated dimer interface mutants A4S, A4T and I113T in terms of their 
thermal stability and propensity to aggregate as well as preliminary stability data on two other 
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mutants, G41D and H80R. Chapter 2 describes the introduction of various structurally and 
chemically diverse ALS-associated hSOD mutations to the pseudo wildtype (pWT) hSOD 
background using polymerase chain reaction-site directed mutagenesis. Very little biophysical 
data is available for many of these mutants and this has served to increase the catalogue of 
available mutants for analysis. In Chapter 3, the thermal stability of fALS-associated mutants 
A4T, A4S, I113T and G41D in the fully metallated (holo) state is determined using differential 
scanning calorimetry (DSC). In addition, the mechanism as well as changes in enthalpy, entropy 
and overall free energy of unfolding are analyzed. Preliminary characterization of the metal 
binding mutant H80R is also included in this chapter. Chapter 4 focuses on the in vitro 
aggregation mechanism of the holo form of the dimer interface mutants A4S and A4T. 
Differences in aggregation propensity of the mutants compared to pWT are considered together 
with thermal stability and epidemiological data to identify any correlations. The overall objective 
is to elucidate the factors that confer toxicity to ALS-associated hSOD mutants, such as specific 
characteristics of the mutants that promote aggregation, and to contribute to the collective 






Chapter 2 Expressing recombinant fALS-associated mutants in 
Escherichia coli 
2.1 Introduction 
2.1.1 Pseudo wildtype hSOD 
 
 Pseudo wildtype hSOD is a C6A/C111S double mutant which replaces the free cysteines 
in position 6 and 111 with alanine and serine, respectively, and will be referred to as pWT. These 
mutations make quantitative thermodynamic analysis possible by preventing the formation of 
aberrant intermolecular disulfide bonds during thermal unfolding experiments, making the 
process reversible (28). PWT hSOD has very similar structure, activity, thermal and chemical 
stability as the wildtype hSOD (24,55).  
2.1.2 The recombinant pHSOD1ASlacIq vector 
 
To enable the expression of fALS-associated mutants in Escherichia coli, each mutation 
of interest is introduced to the pHSOD1ASlacIq vector (Figure 2.1) (31). The pHSOD1ASlacIq 
vector, a derivative of the pBR322 vector (56), is 5747 bp in size and contains the gene for pWT 
(57) connected to a leader sequence from the SOD gene of Photobacterium leiognathi (58), 
which directs the protein to be secreted to the periplasmic space. It also contains an ampicillin 
resistance gene for selection and the genes for the lac repressor and tacI promoter (59) for 
efficient regulation of hSOD expression. The pHSOD1ASlacIq vector was a gift from Professor 
R.A. Hallewell (Department of Biochemistry, Imperial College of Science, Technology and 





Figure 2.1 A schematic of the pPHSOD1ASlacIq vector. The plasmid contains the gene for 
pWT (57) connected to a leader sequence from the SOD gene of Photobacterium leiognathi (58) 
as well as genes encoding ampicillin resistance (ampr), the lac repressor (lacIq) and tacI 
promoter (tacI) (59) (adapted from (60)). 
 
2.1.3 Mutants of interest 
 To date, over 140 point mutations in hSOD have been associated with fALS. These 
mutations are found throughout the protein, illustrated in Table1.1. Nearly all reported mutations 
are dominantly inherited, with the exception of D90A which is recessively inherited (53) and a 
few cases expressing varying degrees of penetrance (61,62). Clearly, it is important to study 
these mutants and determine the properties they possess that that lead to ALS. The mutations 
studied in this thesis are structurally (Figure 2.2) and chemically diverse which include dimer 
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interface mutations (A4S, A4T, I112T, V148G, V148I), metal binding region mutations (H48R – 
copper binding site mutant, H80R – zinc binding site mutant) as well as mutations in the beta 
barrel (G37R, G41D, N86D), which also charge mutations. Table 2.1 is a summary of available 
patient data for the aforementioned mutations.  
 
Figure 2.2 Mutation sites in hSOD associated to ALS that were studied in this thesis. Prepared 
using MolMol (29) and PDB coordinates 1SOS (30). Each monomer contains a Zn2+ and a Cu2+ 
ion depicted as black and orange spheres, respectively. Ther dimer interface, MBR and charge 












Table 2.1 Summary of available patient data on mutants discussed in this thesis as well as the 
average values for fALS and sALS cases. The higher numbers of patients for disease onset age 









A4S >3a (1) 34 (1) (63) 
A4T 1.5 (21) 45.3 (26) (64) 
A4V 1.2 (205) 47.7 (212) (64) 
G37R 17 (27) 36.9 (27) (64) 
G41D 14.1 (15) 45.2 (17) (64) 
H48Rb - - (32) 
H80R 1.5 (1) 24  (1) (65) 
N86Db - - (66) 
I112T 0.9 (2) 44.0 (2) (64) 
I113T 4.3 (38) 56.3 (43) (64) 
V148G 2.1 (11) 43.1 (11) (64) 
V148I 1.7 (5) 28 (4) (64) 
fALSc 4.0  45 (67) 
sALS 2.5 (269) 58.4 (359) (64) 
a Patient was still alive during study 
b Patient data was not reported 
c number of patient not provided 
 
These mutations were introduced into the pHSOD1ASlacIq vector via polymerase chain reaction 
(PCR)-site directed mutagenesis to enable the large scale expression of the mutants required for 








2.2.1 Production of recombinant fALS-associated hSOD plasmids using PCR-
mediated site-directed mutagenesis 
Plasmids encoding fALS-associated hSOD mutants were expressed in the E. coli strain 
XL1-Blue. A modification of the QuickChange® Site Directed Mutagenesis protocol (Strategene, 
La Jolla, CA) was used to produce the fALS-associated hSOD mutants A4S, A4T, G37R, G41D, 
H48R, N86D, I112T, V148G and V148I and an sALS-associated mutant H80R. The primers 
were designed by Joe Gaspar and Dr. Peter Stathopolous. Complementary primers for each 
mutant were used to introduce the desired point mutation into the pHSOD1ASlacIq template 
using PCR. Each primer was designed with the desired mutation about 10-15 bases from each 
end of the primer and contains a minimum Guanine+Cytosine (GC) content of 40%. The primers 
were also designed to end in 2-3 cytosines or guanines. The melting temperature (tm) for each 












Table 2.2 Primer sequences for A4S, A4T, G37R, G41D, H48R, H80R, N86D, I112T and 
V148G/I with %GC and tm. The first line in each primer shows the original sequence while the 
second line shows the primers with the point mutations introduced (X - point mutation, X - 
original nucleotide). tm of the primers were provided by Sigma Genosys Canada, Oakville, 
Ontario.  




1 GCG GCC ACA AAG GCC GTT GCT GTT TTG AAG GG  
GCG GCC ACA AAG TCC GTT GCT GTT TTG AAG GG  
56.25 83.2
A4T
2 GCG GCC ACA AAG GCC GTT GCT GTT TTG AAG GG  
GCG GCC ACA AAG ACC GTT GCT GTT TTG AAG GG  
56.25 83.2
G37R
1 G GTG TGG GGA AGC ATT AAA GGA CTG ACT GAA GGC CTG CAT GG 
G GTG TGG GGA AGC ATT AAA CGT CTC ACT GAA GGC CTG CAT GG  
54.76 86.4
G41D
1 C ATT AAA GGA CTG ACT GAA GGC CTG CAT GGA TTC CAT GTT C  
C ATT AAA GGA CTG ACT GAA GAC CTG CAT GGA TTC CAT GTT C  
43.90 79.8
H48R
1 C CTG CAT GGA TTC CAT GTT CAT GAG TTT GGA GAT AAT ACA GC  
C CTG CAT GGA TTC CAT GTT CGC GAG TTT GGA GAT AAT ACA GC  
47.62 83.1
H80R
1 CCA AAG GAT GAA GAG AGG CAT GTT GGA GAC TTG GGC AAT G  
CCA AAG GAT GAA GAG AGA CGT GTT GGA GAC TTG GGC AAT G 
50.00 83.0
N86D
1 G CAT GTT GGA GAC TTG GGC AAT GTG ACC GCG GAC AAA GAT G  
G CAT GTT GGA GAC TTG GGA GAC GTG ACC GCG GAC AAA GAT G  
56.10 87.6
I112T
2 CA GGA GAC CAT TCC ATC ATT GGC CGC ACA CTA G 
CA GGA GAC CAT TCC ACC ATT GGC CGC ACA CTA G  
57.58 82.4
V148G
2 CGT TTG GCT TGT GGT GTA ATT GGG ATC GCC C  
CGT TTG GCT TGT GGT GGA ATT GGG ATC GCC C  
58.06 84.1
V148I
2 CGT TTG GCT TGT GGT GTA ATT GGG ATC GCC C  
CGT TTG GCT TGT GGT ATA ATT GGG ATC GCC C  
51.61 78.9
1 Primers designed by Joe Gaspar 
2 Primers designed by Dr. Peter Stathopolous 
 
Table 2.3 lists the components required for the PCR master mix. The buffer (Buffer 1) as well as 
DNA polymerase mix was obtained from the Expand Long Template PCR System kit (Roche 
Diagnostics, Indianapolis, IN). To decrease the effects of primer dimerization, the 
complementary primers of each mutation were thermocycled separately in sterile PCR tubes, 
containing 24.25 µL of master mix and 0.25 μL of one of the two complementary primers (final 
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concentration 0.25 mM) for five cycles before being pooled together. Thermocycling was done 
using a TC-512 Thermal Cycler (TECHNE, Cambridge) using the conditions listed in Table 2.4. 
The PCR products were then treated with DpnI endonuclease, which digests methylated or 
hemimethylated DNA, for 1 hour in a 37 °C water bath. Since the synthesized DNA is 
unmethylated, DpnI will only digest the template plasmid. The recombinant plasmids were 
stored at -20 °C for further analysis. 
Table 2.3 PCR components for master mix. Volumes listed are for final amount after 





Expand Long Template PCR System Buffer 1 5 - 
pHSOD1ASlacIq template 0.5 ~ 1.75 mM 
dNTPs 0.5 0.25 mM each 
MilliQ H2O 42.5 - 
Total 48.5  
 
 
Table 2.4 Conditions for thermocycling 
PCR stages Conditions 
Initial denaturation 92 °C for 5 min 
Pause  Add 0.5 μL Expand Long Template PCR System DNA 
polymerase mix 
Initial amplification  
(5 cycles) 
92 °C for 30 sec (denaturation) 
55 °C for 1 min (annealing) 
68 °C for 20 min (elongation) 
Pause  Complementary tubes pooled together 
Final amplification 
(15 cycles) 
92 °C for 30 sec (denaturation) 
55 °C for 1 min (annealing) 
68 °C for 20 min (elongation) 






2.2.2 Expression of recombinant plasmids   
The DpnI digested plasmids were transformed into XL1-Blue electrocompetent E. coli 
cells as described elsewhere (68,69). Briefly, 1 µL of DpnI digested PCR product was 
electroporated with 40 µL of XL1-Blue E. coli cells and incubated in 1 mL Super Optimal broth 
with Catabolite repression (SOC; 0.4% (w/v) glucose, 20.0 g tryptone, 5.0 g yeast extract, 0.5 g 
NaCl, 0.01 M MgSO4 per 1 L) at 37 °C for 1 hour.  Electroporation was done using the BioRad 
E. coli Pulser (BioRad Laboratories, Inc.) for ~1 s at 1.80 kV. XL1-Blue cells have the ability to 
repair nicks in the mutant plasmid as well as confer tetracycline resistance. The transformed cells 
were plated on Luria Broth (LB) agar (10.0 g tryptone, 5.0 g yeast extract, 10.0 g NaCl, 16 g 
agar per 1 L) containing ampicillin (100 μg/mL) and tetracycline (10 μg/mL) to select for XL1-
Blue cells that have taken up the pHSOD1ASlacIq plasmid. Small scale protein preparations and 
osmotic shock (refer to Section 3.2.2.1) were performed to obtain protein to be run on a mass 
spectrometer. Once the protein masses have been confirmed, the HiYieldTM Plasmid Mini Kit 
(RBC BioScience) protocol for high copy number plasmid was used to purify the plasmids. 
These plasmids were stored at -20 °C for further use.  
2.2.3 Positive electrospray ionization mass spectrometry 
Positive electrospray ionization mass spectrometry was used to confirm the masses of the 
expressed proteins (Micromass Q-TOF Ultima). Purified samples were diluted to approximately 
1 M in 50:50 acetonitrile:water with 0.2% formic acid and injected into the mass spectrometer 
at a flow rate of 1 L/min, capillary voltage of 3.2 kV, cone voltage of 80 V and m/z range of 




2.3 Results  
2.3.1 Obtaining recombinant fALS-associated hSOD plasmids using PCR-
mediated site-directed mutagenesis 
 The PCR-mediated site-directed mutagenesis introduces desired mutations to the 
pHSOD1ASlacIq template as well as amplifies the amount of recombinant mutant plasmid. The 
PCR products were run on 0.7% agarose gels to determine if the process was successful. Figure 
2.3 is a set of PCR products containing strong, single bands for each mutant, indicating that the 
respective primers annealed with high specificity and that each sample was successfully 
amplified. The mutant I112T was never successfully amplified (data not shown) while A4T was 
obtained during my CHEM 494 with Dr. E. M. Meiering.  
 
Figure 2.3 PCR products from PCR-mediated site directed mutagenesis of ALS-associated 
hSOD mutants. The pHSOD1ASlacIq template is 5747 bp in size. Samples were run on a 0.7% 
agarose gel at a constant voltage of 100 kV. *GeneRuler™ 1 kb DNA Ladder (Fermentas 
Canada Inc., Burlington, Ontario)  
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2.3.2 Expression of recombinant hSOD 
 The recombinant hSOD were transformed into XL1-Blue E. coli and, at least, two 
colonies from each transformation were grown in LB broth, purified and ran on an SDS-PAGE 
to determine the level of expression of the PCR products (V148I transformants only produced 
one colony). Figure 2.4 is an SDS-PAGE of the expressed proteins from the plasmids in Figure 
2.3. In this instance, all the plasmids produced hSOD and there did not appear to be a drastic 
decrease in protein expression for any of the samples. 
 
 
Figure 2.4 SDS-PAGE of recombinant hSOD mutants obtained expression. Purified pWT 
(lane A7 and B8) was used as a marker for hSOD. 
 
2.3.3 Confirmation of recombinant hSOD mass 
 After it was determined that the recombinant mutants expressed hSOD, the mass of the 
recombinant mutants were checked via mass spectrometry to verify if the correct mutation had 
been introduced. Table 2.5 reports the final masses for the successfully obtained mutants and a 
representative mass of the unsuccessful mutants. A protein of known mass was used as a 
standard to obtain any offset the mass spectrometer might have. The mutants A4S, A4T, G37R, 
G41D, H80R, V148G and V148I were successfully obtained. Due to the similarity in mass of 
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N86D to pWT, the N86D plasmid was sent for sequencing which revealed that the mutagenesis 
was unsuccessful.  
Table 2.5 Summary of recombinant hSOD masses. Listed in bold are mutants thatw ere 
succefully obtained. 







A4S 15768.50 -1.99 15770.49 15770.39 Y 
A4T 15783.00 -1.42 15784.42 15784.42 Y 
G37R 15851.50 -1.99 15853.49 15853.52 Y 
G41D 15810.00 -1.99 15811.99 15812.42 Y 
H48R 15769.00 -1.42 15770.42 15773.43 N 
H80R 15771.50 -1.99 15773.49 15773.43 Y 
N86D 15752.20 -1.99 15754.19 15755.37 N 
I112Ta 15753.80 n/a n/a 15742.34 N 
V148G 15711.00 -1.42 15712.42 15712.31 Y 
V148I 15767.00 -1.42 15768.42 15768.41 Y 
a  A standard was not ran on the day I112T was checked, however, the apparent mass was sufficiently different from 
the expected mass to conclude that the PCR-mediated site directed mutagenesis was not successful. 
 
2.4 Discussion 
 PCR-mediated site directed mutagenesis is a useful method for introducing mutations to a 
template plasmid. Of the 10 mutations tried, 7 were successfully obtained. The PCR attempts of 
I112T and N86D resulted in pWT which could be due the 3’→5’ exonuclease proofreading 
activity of the Tgo polymerase contained in the Expand Long Template PCR System DNA 
polymerase mix. It is not clear why, despite several attempts, we have been unsuccessful in 
obtaining I112T. On the other hand, the primers for H48R and N86D contain more than one 
point mutation. It would be worth considering redesigning the primers for all 3 mutants to 
increase the efficacy of mutagenesis. The characterization of the mutant proteins is described in 
the following chapters. Chapter 3 will focus on determining the stability of holo A4S, A4T and 
G41D and comparing them with pWT. This chapter will also include preliminary data on H80R. 
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In Chapter 4, the propensity for aggregation of holo A4S and A4T is studied to better understand 







































Chapter 3 Stability of ALS-associated hSOD mutants 
 
3.1 Introduction 
 PCDs are a fast growing subset of modern world diseases, largely due to the complicated 
nature of the diseases and the lack of known causes. With many PCDs associated with natively 
folded proteins, mutations associated with the hereditary forms of the diseases tend to destabilize 
the native state (70). Similarly, studies on purified ALS-associated hSOD mutants have revealed 
that the mutants are destabilised compared to pWT in the holo state (71-73). The destabilization 
of the native state can in turn increase the protein’s propensity to unfold/misfold or populate 
aggregation prone intermediates. Mutant hSOD expressed in rabbit reticulocyte lysate have also 
been shown to be less resistant to proteolysis (74) and hSOD peptide fragments have been found 
in aggregates from a mutant hSOD mouse model of ALS (49). In this chapter, the thermal 
stability of the dimer interface mutants A4S, A4T and I113T, in the holo form, will be 
characterized using differential scanning calorimetry and compared to pWT. In addition, some 
preliminary DSC data and analysis on G41D and H80R are presented.  
3.1.1 Differential scanning calorimetry 
The thermal stability of hSOD can be measured using differential scanning calorimetry 
(DSC) (75). DSC measures the difference in heat capacity between a reference cell, containing 
only buffer, and a sample cell, containing protein in buffer, as it is heated at a constant rate 
through its unfolding transition (76). As the protein unfolds, more energy is required to heat the 
sample cell at the same rate as the reference cell, which produces an endothermic peak in the 
heat capacity curve (illustrated in Figure 2.1). The area under the unfolding transition peak gives 
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the calorimetric enthalpy of unfolding (∆ ) and reflects the actual change in the enthalpy of 
the system. ∆  can be expressed by Equation 3.1: 
   ∆    Equation 3.1 
where ∆  is change in heat capacity upon unfolding and  is temperature.  
 
Figure 3.1 The specific heat capacity function of a globular protein. ∆  is the difference 
between the heat capacity of the native ( , ) and the unfolded ( , ) states which are indicated 
by dashed and dotted lines, respectively, and  is the temperature where = 0.58 (figure 
obtained from (68)). 
 
The van’t Hoff enthalpy (∆ ) can be obtained by fitting the heat capacity curve to an 
appropriate unfolding model. The ratio of ∆  to ∆  will reflect how well the data fits the 
proposed model as well as the size of the cooperative unit of unfolding (76). In the case of 
hSOD, unfolding can be fit to a dimer two-state unfolding model, 
 N2 ↔ 2U  
where the unfolding transition occurs between native dimer (N2) and unfolded monomers (2U) 
(28).  
 For a dimer two-state unfolding model, the unfolding transition is expected to be 
asymmetrical and the  , the temperature at which half of total dimer is unfolded, is expected to 
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increase with protein concentration (28). A ∆ /∆  of one indicates that the dimer two-state 
unfolding model fits the data well. On the other hand, a ratio of greater than one suggests a 
cooperative unit larger than dimer, e.g. the presence of aggregates, while a ratio of less than one 
indicates a cooperative unit smaller than dimer, e.g. the presence of an intermediate (28,75,76). 
The  correlates to the stability of the protein and most fALS-associated hSOD mutations have 
been found to be less stable than pWT (28,68,77,78). The DSC trace also provides information 
on the metallation state of the sample as mismetallated protein samples result in traces with 
multiple peaks or shoulders at lower temperatures. In addition to having lower stability, most 
fALS-associated hSOD mutants have a ∆ /∆  larger than unity in the apo form, which 
indicates an increased propensity to aggregate in vitro (68,77,79). It is found that dimer interface 
mutants A4S, A4T and I113T are destabilized compared to pWT in the holo state. They also 
have slightly weakened dimer association compared to pWT, consistent with the location of 
these mutations in the dimer interface. These findings agree with previous data on apo dimer 











3.2.1 Expression of recombinant hSOD 
 
The E. coli strain SOD(-/-) (80) was used for large scale protein expression. SOD(-/-) E. 
coli do not produce the two endogenous bacterial SODs, manganese SOD and iron SOD, and are 
resistant to chloramphenicol and kanamycin (80). Large scale protein expression was performed 
as described previously (68). Briefly, the recombinant plasmids were transformed into SOD(-/-) 
E. coli (Section 2.2.2) and plated on LB agar containing ampicillin (100 µg/mL), 
chloramphenicol (30 µg/mL) and kanamycin (30 µg/mL) and incubated overnight at 37 °C. 
Isolated colonies were grown overnight, at 37 °C, in LB media containing ampicillin (100 
µg/mL), chloramphenicol (30 µg/mL) and kanamycin (30 µg/mL). A 1/100 dilution of the 
overnight cultures was used to inoculate 6 x 1 L 2TY media (16 g bacto-tyrptone, 10 g yeast, 10 
g NaCl per 1 L) containing ampicillin (100 µg/mL), chloramphenicol (30 µg/mL) and kanamycin 
(30 µg/mL). The 2TY cultures were incubated with shaking (200 rpm) at 37 °C until an optical 
density of 0.6-0.8 at 600 nm was obtained. HSOD expression was then induced by adding 
isopropyl-beta-D-thiogalactopyranoside (IPTG), CuSO4 and ZnSO4 to final concentrations of 
0.25 mM, 0.5 mM and 0.01 mM, respectively. The cultures were incubated with shaking for an 
additional 8 hours at 37°C, then harvested via centrifugation (4500 x g for 15 min) and the cell 
pellet was stored at -80 °C until further purification. 
3.2.2 Purification of recombinant hSOD 
3.2.2.1 Osmotic shock protocol 
The osmotic shock (OS) method (81) was used to obtain hSOD from the periplasmic 
space of the SOD(-/-) cells. Briefly, the cells were resuspended in cold 20 mM Tris-HCl pH 7.5 
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(25 mL/1 L culture) buffer containing sucrose (20% (w/v) final concentration) and 
ethylenediaminetetraacetic acid (EDTA; final concentration of 15 mM), incubated in on ice for 
20 min with gentle agitation and centrifuged at 4000 x g for 25 min. The cell pellet was then 
resuspended in cold MilliQ (Millipore Ltd., Bedford, MA) water (20 mL/1 L culture) to release 
the periplasmic proteins into solution, incubated on ice for 20 min with gentle agitation and 
centrifuged at 4500 x g for 45 minutes. The supernatant was flash frozen in liquid nitrogen and 
stored at -80 °C until further purification. 
3.2.2.2 Heat treatment and copper charging 
The OS supernatant was diluted to a concentration of ~ 0.8 mg/mL in 20 mM Tris-HCl 
pH 7 buffer and heated to 70 °C with CuSO4 (final concentration of ~1.4 mM) for 25 mins. The 
CuSO4 is added to ensure proper metallation of hSOD and the high temperature denatures most 
other periplasmic proteins present in the osmotic shock mixture, which can then be removed via 
centrifugation at 10 000 x g for 20 min. H80R was heated at 55 °C due to its lower stability. 
3.2.2.3 Hydrophobic interaction chromatography 
The final purification step was carried out as described previously (68). Briefly, hSOD 
was eluted from a hydrophobic interaction column using a high to low salt gradient. Fractions 
containing hSOD were pooled together and dialyzed against MilliQ water with 4 exchanges over 
24 hours using 6-8 kDa cutoff dialysis tubing (Spectra/Por® molecularporous membrane tubing; 
Spectrum Laboratories, Inc., Rancho Dominguez, CA). The dialyzed solution was concentrated 
using an Amicon ultrafiltration device with a 10 kDa cutoff membrane (YM10 Amicon 
ultrafiltration regenerated cellulose membrane; Millipore Ltd., Bedford, MA), filtered with a 
0.22 m Acrodisc® syringe filters (Pall Canada Ltd., QC) and stored at -80 °C. 
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3.2.3 Preparation of apo protein 
  The apo form (metal free form) of the protein was made using methods described 
previously (68,73). Briefly, the holo protein was diluted to a concentration of 0.5-1.0 mg/mL and 
dialysed against EDTA (100 mM EDTA, 50 mM sodium acetate, pH 3.8) and salt (100 mM 
sodium chloride, 50 mM sodium acetate, pH 3.8) solutions, followed by MilliQ water using a 3.5 
kDa cutoff dialysis tubing. Four exchanges over 24 hours were done for each solution/MilliQ 
water. The dialyzed protein was concentrated using an Amicon ultrafiltration device with a 3 
kDa cutoff membrane, filtered with a 0.22 m Acrodisc® syringe filters and stored at -80 °C. 
3.2.4 Protein quantification 
3.2.4.1 Lowry assay for protein concentration 
A modified version of the Lowry assay (82) was used to determine protein concentrations 
using bovine serum albumin (BSA) as standards (68). Briefly, 25 L of BSA standards/samples 
were incubated with 100 L of 1 M NaOH for 15 min at room temperature. Then, 1 mL copper 
solution (2% Na2CO3, 0.01% CuSO4, 0.02% sodium tartrate) was added to the standards/samples 
and incubated at room temperature for 30 min. Finally, 100 L 50% Folin reagent (Sigma-
Aldrich, St. Louis, MO) was added and incubated at room temperature for 30 min at which point, 
the absorbance of each sample at 750 nm was determined using a Cary 300 Bio UV-Visible 
Spectrophotometer (Varian Inc., Mississauga, ON).  
3.2.4.2 Pyrogallol activity assay for holo hSOD 
The pyrogallol activity assay, previously described by Marklund and Marklund (83), was 
used to determine the specific activity of the holo hSOD mutants (also described in detail in Dr. 
Jessica Rumfeldt`s thesis (68)). The rate of pyrogallol autooxidation depends on the availability 
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of superoxide and can be monitored spectrophotometrically (at 420 nm) by a colour change from 
clear to yellow-brown. The addition of hSOD to pyrogallol will inhibit pyrogallol’s 
autooxidative ability since hSOD competes for superoxide. The specific activity of hSOD will be 
measured in Units/mg where 1 unit is the amount of hSOD required to reduce the rate of 
pyrogallol autooxidation by 50%. The average specific activity of holo pWT is approximately 
1800 U/mg (73). Many mutants retain full activity; however, a lower than expected specific 
activity could indicate that the protein is not properly metallated. It may also indicate that a 
fraction of the protein in the sample is not functional, or the sample as a whole has lower 
dismutase activity, or a combination all three causes. 
3.2.5 Differential scanning calorimetry 
Measurements were made using methods previously established in the Meiering 
laboratory (28,68). Briefly, samples were prepared in 20 mM HEPES pH 7.8 and degassed prior 
to loading into the calorimeter. All measurements were made using a MicroCal LLC VP-DSC 
(MicroCal Inc., Northampton, MA) and scanned versus dialysate. Initial DSC scans of holo and 
apo proteins were done from 15-100 °C and 10-90 °C, respectively, at a rate of 1 °C/min. 
The data were then fit to a dimer 2-state unfolding model (Equation 3.2) as well as a 
monomer 2-state unfolding model (Equation 3.3) as described elsewhere (75,77,79) using the 
following equations: 
   1    Equation 3.2 
    1    Equation 3.3 
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where   is the total specific heat absorption at absolute temperature, ;  is a 
temperature-independent constant equal to ∆ /∆  x molecular weight of the dimer; ∆  
is the specific enthalpy of unfolding at ;  is the fraction of unfolded protein at ;  is the 
universal gas constant;  and  are the intercepts and  and  are the slopes of the native and 
unfolded baselines, respectively. All DSC data fitting was done using Microcal Origin 5.0. The 
fit provides a fitted  (the temperature when  = 0.5), a  value and a ∆  that is the 
specific enthalpy of unfolding at  (in cal/g). The ∆  (in cal/mol) can then be obtained by 
multiplying ∆  with the molecular mass of the unfolding unit (dimer or monomer) to 
determine the ∆ /∆ . The DSC scans for holo hSOD were fit to 75% of the endothermic 
peak due to the presence of an exotherm at high temperatures. The exotherm is probably from 
irreversible protein aggregation at the high temperatures so that the unfolded baseline is not well 
defined (77). 
 For a 2-state unfolding process,  should vary with protein concentration as described 
by the following equation (75): 
 constant 1 ln  ∆  constant Equation 3.4 
where  is the total protein concentration of monomers,  is the gas constant and  is the 
molecularity of the unfolding subunit . Rearranging equation 3.4 indicates that the slope, , for a ln  versus 1⁄  plot is 
  ∆  Equation 3.5 




3.3.1 Thermal Stability of fALS-associated hSOD mutants  
3.3.1.1 Thermal unfolding of holo dimer interface mutants fit a dimer 2-state 
unfolding model 
 It has been shown previously that holo hSOD thermal unfolding follows a dimer 2-state 
model (68,77,79). Figure 3.2 illustrates that holo A4S, A4T and I113T as well as G41D are all fit 
quite well by the dimer 2-state unfolding model and less well fit by the monomer 2-state 
unfolding model. This is also indicated by the χ2 values which are lower for fits to the dimer 2-
state model. Dimer 2-state unfolding produces an asymmetrical endothermic peak and has a 
concentration-dependent . The monomer 2-state fits in Figure 3.2 (B, D, F, H) systematically 
deviates from the thermograms, where the fits predict a more symmetrical endotherm compared 
to the data. This is readily apparent around the s and at the beginning of the endothermic peak.  
The concentration dependence of the dimer interface mutants is illustrated in Figure 3.3 
where the  gradually increases with increasing protein concentration. Figure 3.4 are plots of 
the predicted concentration dependence of s for pWT and the dimer interface mutants 
calculated from the average fitted parameters to the dimer 2-state unfolding model from Table 
3.1. Figure 3.4 shows that the concentration dependence of the experimental s of holo pWT, 
A4S, A4T and I113T fall within the predicted concentration dependence of their s at the lower 
protein concentration range. All three mutants have experimental s that deviate from their 
predicted s at higher protein concentrations. This may be due to their lower stability, leading 
to an increased propensity to aggregate at higher concentrations. Alternatively, at may be due to 
increased population of monomer at lower concentrations. Table 3.1 lists the DSC fitted 
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parameters for holo pWT, A4S, A4T and I113T. Holo pWT’s ∆ /∆  of one indicates that 
holo pWT fits the dimer 2-state unfolding model well. The ratios for A4S, A4T, A4V and I113T 
are 0.85±0.07, 0.95±0.13, 0.72±0.18 and 0.89±0.07, respectively, which are quite close to 1. The 
slightly decreased values could be indicative of the formation of a monomer intermediate, which 
would be expected since the mutations are near the dimer interface. The ∆ /∆  for all the 
mutants also increase with protein concentration, with ∆ /∆  values closest to unity at 
higher protein concentrations. This indicates that the dimer is more populated at higher protein 
concentrations. 
From Equation 3.5, the molecularity of the unfolding subunit can be calculated using the 
following equation: 
 Molecularity  ∆  1 Equation 3.6 
where ∆  is the average ∆  from Table 3.1,  is the gas constant and  is the slope from a 
lnP versus 1/  plot. Table 3.2 list the molecularity for holo pWT and dimer interface mutants 
as well as dissociation constants, Kd, of the dimer interface mutants in the holo and apo state. The 
molecularity for pWT is 1.91, which is close to the expected value of 2 for dimer unfolding. On 
the other hand, the dimer interface mutants all have lower molecularities compared to pWT, 





Figure 3.2 Dimer 2-state and monomer 2-state fits of holo dimer interface mutants A4S (A 
and B), A4T (C and D), I113T (E and F) and G41D (G and F) at protein concentrations of 0.5 
mg/mL, 0.39 mg/mL, 0.7 mg/mL and 1.00 mg/mL, respectively. The dimer 2-state fits are on the 
left while the monomer 2-state fits are on the right. The experimental data and the fits are 




Figure 3.3 Protein concentration dependence of holo pWT and holo dimer interface 
mutants. DSC thermograms of pWT (A), I113T (B), A4S (C) and A4T (D) at different 
concentrations are offset for clarity and arranged in increasing protein concentration from bottom 
to top. The experimental data and the dimer 2-state fits are represented by solid and dashed lines, 







Figure 3.4 Protein concentration dependence of  for holo pWT (A), holo I113T (B), holo 
A4S (C) and holo A4T (D) based on the dimer 2-state model. The squares are the fitted  
values while the solid lines are the predicted  values for each mutant calculated from averaged 












Table 3.1 Fitted dimer 2-state parameters for holo dimer interface mutants A4S, A4T, A4V 









 at  c 
(kcal/°C/mol) 
pWT* 0.20 91.6±0.2 265.5±15.1 228.8±11.5 1.16 4.12 
pWT* 0.50 92.4±0.4 256.5±22.8 231.4±18.3 1.11 4.50 
pWT* 0.50 91.6±0.5 230.6±24.3 220.6±20.9 1.05 5.37 
pWT* 1.00 92.5±0.5 269.0±30.5 255.0±26.0 1.05 5.80 
pWT* 1.87 93.2±0.3 276.9±20.5 270.5±17.8 1.02 7.07 
pWT* 6.30 94.2±0.3 238.7±20.2 279.8±20.4 0.85 3.73 
Mean±S.D. 1.04±0.10 5.10±1.23 
A4S 0.10 86.7±0.0 208.2±3.6 256.1±3.1 0.81 3.85 
A4S 0.30 86.5±0.2 184.4±10.1 243.1±11.2 0.76 2.92 
A4S 0.30 87.8±0.1 234.2±7.1 276.8±7.0 0.85 3.57 
A4S 0.45 87.3±0.0 212.9±3.8 217.0±2.1 0.98 3.95 
A4S 0.50 88.2±0.0 238.3±3.0 279.8±2.1 0.85 5.02 
A4S† 0.95 88.5±0.0 238.2±5.2 261.8±3.1 0.91 11.21d
A4S† 1.00 87.8±0.0 211.1±3.1 253.5±1.7 0.83 4.32 
A4S† 2.95 89.1±0.0 214.9±2.5 260.1±1.3 0.83 4.60 
Mean±S.D. 0.85±0.07 4.03±0.69 
A4T 0.16 85.2±0.1 187.9±4.0 254.8±4.2 0.74 1.74 
A4T 0.20 85.4±0.1 197.3±6.3 195.5±5.0 1.01 0.04 
A4T 0.38 85.6±0.0 209.8±2.2 185.2±1.0 1.13 3.78 
A4T 0.39 85.8±0.0 201.5±2.1 251.4±1.3 0.80 3.33 
A4T 0.44 86.2±0.1 215.4±7.7 243.6±7.6 0.88 8.13 
A4T 0.59 86.6±0.0 230.3±2.0 239.5±0.9 0.96 6.22 
A4T† 1.08 86.2±0.1 221.5±4.6 207.3±3.4 1.07 4.77 
A4T† 4.34 87.3±0.0 224.1±1.6 229.9±0.8 0.97 4.34 
Mean±S.D. 0.95±0.13 4.04±2.51 
A4V‡ 0.20 86.9±0.0 197.7±1.4 373.9±1.5 0.53 5.88 
A4V‡ 0.50 87.2±0.0 204.2±1.4 333.8±1.0 0.61 6.49 
A4V‡† 1.00 87.4±0.0 208.4±1.7 232.0±0.8 0.90 3.44 
A4V‡† 5.00 88.4±0.0 237.5±3.1 279.9±1.5 0.85 4.88 
Mean±S.D. 0.72±0.18 5.17±1.33 
I113T 0.09 86.8±0.0 200.7±2.0 253.8±1.4 0.79 3.42 
I113T† 0.70 88.1±0.0 242.0±2.3 248.2±1.6 0.97 4.19 
I113T† 1.48 88.2±0.0 231.6±2.1 257.1±1.5 0.90 5.51 
I113T† 2.76 89.0±0.0 260.0±1.6 288.3±0.8 0.90 5.53 
Mean±S.D. 0.89±0.07 4.66±1.04 
G41D     1.00 85.3±0.4 235.8±5.7 225.2.7±4.4 1.05 6.13 
* Data obtained and fitted by Dr. Jessica A. O. Rumfeldt (68).  ‡ Data obtained by Dr. Jessica A. O. Rumfeldt (68) and fitted by Helen Stubbs. 
† Datasets used to calculate free energy plots in Figure 3.5 (B) as well as thermodynamic parameters in Table 3.3. 
a Errors for  of individual fits could not be reliably calculated as they are based on uncertainties from five different 
variables. 
b Errors obtained from fitting program. 
c Errors derived using standard procedures (84) from errors in fitted  and  obtained from fitting program. 




Table 3.2 Dissociation constants, Kd, and molecularity for pWT and dimer interface 
mutants. The molecularity was calculated using equation 3.4. 
hSOD  Kd apo 
37 °C a 
( M) 
Kd holo 
65 °C b 
( M) 
Molecularity 
pWT  - - 1.91 
A4S  1.6±0.6 - 1.86 
A4T  5.1±1.2 - 1.57 
A4V  10.0±3.1 48±17 1.39 
I113T  3.9±0.1 33±10 1.54 
a Data from (79). 
b Data from (77). 
 
3.3.1.2 Holo mutants are destabilized relative to holo pWT 
 DSC reveals that dimer interface mutants A4S, A4T and I113T as well as G41D are 
destabilized relative to pWT. This is clearly illustrated in Figure 3.5 (A) where the mutants have 
lower s compared to pWT and in Table 3.3 where the difference in  of the mutants relative 
to pWT range from -4.7 °C to -7.4 °C. The negative values of ∆∆  (Table 3.3), the change in ∆  
of the mutant relative to pWT, and the shift to lower temperatures of the free energy diagrams of 
the mutants relative to pWT (Figure 3.3 B) also indicate that the mutants are destabilized 
compared to pWT. Due to errors that may be propagated through long extrapolations of ∆ , the ∆∆  is reported at  (88.3 °C - short extrapolation), as well as at physiological temperature 
(25 °C - long extrapolation).  
The change in Gibbs free energy of unfolding, ∆ , for pWT  was determined using the 
average fitted parameters from Table 3.1. On the other hand, ∆  for the dimer interface mutants 
were determined using only the average fitted parameters of datasets at higher protein 
concentrations (labelled †) from Table 3.1. This was done as the datasets at higher protein 
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concentrations are more representative of dimer 2-state unfolding and will provide a more 
relevant comparison with pWT values. A constant ∆  of 2.75 kcal/mol (as determined 
previously for pWT by Dr. Jessica Rumfeldt (68)) instead of the average ∆ s from Table 3.1 as 
the ∆ s from the DSC fits are associated with considerable error (85) owing to the lack of a 
well defined unfolded baseline. The ∆ s at  and 25 °C were calculated using the following 
equations (68,77): 
 ∆  ∆  ∆  Equation 3.7 
 ∆  ∆  ∆  Equation 3.8 
 ∆  ∆  ∆  Equation 3.9 




Figure 3.5 ALS-associated mutants are destabilized relative to pWT in the holo state. (A) 
DSC thermograms of holo pWT, I113T, A4S, A4V, A4T and G41D at protein concentrations of 
1.00 mg/mL, 0.70 mg/mL, 1.00 mg/mL, 1.00 mg/mL, 1.08 mg/mL and 1.00 mg/mL, 
respectively. The thermograms are arranged from highest to lowest  (top to bottom) where the 
solid lines are experimental data and the dashed lines are the fits to the dimer 2-state unfolding 
model. The thermograms are also offset for clarity. (B) Free energy diagrams of each mutant 
relative to pWT in the holo state. pWT is shown as a dashed line while A4T, A4S, A4V, G41D 
and I113T are shown in solid lines and indicated with arrows. The free energy plots were 
calculated from average fitted values from higher protein concentration datasets listed in Table 
3.1 as they are more representative of dimer 2-state unfolding. The intersection of the “horizontal 







Table 3.3 Thermodynamic parameters of holo fALS-associated mutants A4S, A4T, I113T and G41D compared to pWT. Only 
datasets at higher protein concentrations (Table 3.1 †) for the dimer interface mutants were used in the calculation for the parameters 
in this table to avoid any bias that may be contributed from the presence of a monomer intermediate. 
Holo 
isomer 






Δ  (25 °C) 
(kcal/mol) 








Δ∆ d  
(kcal/mol) 
pWT* - 10.1±0.4 0.66±0.05 35.4±3.2 0.13±0.05 - - - - 
A4S -4.8 6.8±0.3 0.59±0.04 28.1±2.8 0.06±0.04 -3.3 -7.4 -0.06 -26.7 
A4T -6.5 5.7±0.5 0.62±0.01 28.7±1.2 0.09±0.01 -4.4 -6.8 -0.04 -17.9 
A4V‡ -5.8 6.2±0.4 0.60±0.05 28.1±2.9 0.07±0.05 -3.9 -7.4 -0.05 -23.7 
I113T -4.7 6.8±0.2 0.66±0.04 32.1±2.3 0.13±0.04 -3.3 -3.3 0.00 -3.5 
G41D -7.4 4.9 0.66 30.6±0.5 0.13±0.00 -5.1 -4.9 0.00 -3.6 
a  at  0.5 mg/mL from Figure 3.5 (B). 
b Change in the ∆  of the mutants relative to pWT (∆∆  ∆  ∆ ). 
c Change in the ∆  of the mutants relative to pWT (∆∆  ∆  ∆ ). 
d Change in the ∆  of the mutants relative to pWT (∆∆  ∆  ∆ ). 
* Data from (68). 
‡ Data from (68) and fit by Helen Stubbs. 
 = 88.3 °C is the average  for pWT and mutants from Table 3.1. 







3.3.2.1 Initial Data 
When H80R was initially obtained from the small scale purification, the mass spectrum 
of its OS contained not only a peak corresponding to H80R but also a fairly large peak 
corresponding to an approximately +18.5 Da species. Another mass spectrum was obtained after 
a 16 days incubation period at room temperature. Figure 3.6 illustrates the peak intensities of 
H80R and the +18.5 Da peak before and after the 16 day incubation. Over time the +18.5 Da 
species increased as the H80R peak decreased. This indicated that H80R was being modified 
over time. Figure 3.6 also illustrates that this modification process began either before or during 
the protein purification process as the pre-incubation sample contained the modification. The 
addition of 18.5 Da could correspond to the mass of a molecule of water, suggesting that the 
protein may have been cleaved somewhere between the intramolecular disulfide bonds (C57-




Figure 3.6 Change in H80R species distribution over time. The spectrum indicates conversion 
of H80R into H80R+18.5 kDa species. The sample is the OS supernatant form a small scale 
purification of H80R. 
 
3.3.2.2 Identifying the site of cleavage 
 A time-dependant modification as observed for H80R has never been observed for any 
other hSOD mutants previously studied in our laboratory. X-ray crystallography data have 
shown that although H80R does not bind metal in the zinc site, it does contain a metal ion, 
presumably zinc or copper, in the copper binding site (86). Considering that H80R is a zinc 
binding site mutant, it may be possible that the active site copper can undergo some kind of 
aberrant chemistry resulting in the self-cleaving of H80R. Another possible scenario could be 
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decreased stability of H80R due to the lack of zinc coordination (86), increasing its sensitivity to 
proteolysis. 
To determine where the protein was being cleaved, the OS from a small scale expression 
was purified using a Nanosep 3K Omega centrifugal device (Pall Canada Ltd., QC) to remove 
the sucrose as well as any small fragments that may be in the sample. The OS and the slightly 
purified sample were incubated for 17 hours at 37 °C and at room temperature. Figure 3.7 is an 
SDS-PAGE of H80R incubated at the different temperatures. The unreduced samples (Figure 3.7 
Lanes 9-14) contain 2(3) major bands of ~15 kDa in size. We suspect that the larger band(s) 
corresponds to the cleaved species as it would have a more expanded structure and travel slower 
through the gel. The same samples reduced with 10% β-mercapthoethanol (βme) (Figure 3.7 
Lanes 3-7) reveal that one of the larger bands has been replaced by 2 smaller fragments of ~8.1 
kDa in size.  
 The specific masses of the fragments were determined using mass spectrometry. sample 
was fully reduced. Figure 3.8 shows the reduced (B) and non-reduced (A) mass spectra of the 
slightly purified H80R that had been incubated for 17 h at 37 °C. To ensure that the entire 
sample in Figure 3.8 (B) was reduced, the sample was incubated overnight under reducing 
conditions in 1% βme. Figure 3.8 (A) is the spectrum for the non-reduced sample and contains 
peaks for disulfide intact H80R (15772 Da) and disulfide intact H80R+18.5 Da (15790.5 Da) 
while Figure 3.8 (B) is the spectrum for the reduced sample and contains reduced H80R 
(15774.5 Da), no H80R+18.5 Da peak and peaks at 7211 Da and 8580 Da. Using the MassLynx 
program, it was determined that the 7211 Da fragment corresponds to residues 1-69 while the 
8580 Da fragment corresponds to residues 70-153. Therefore, H80R was being cleaved between 
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residue R69 and K70. Both spectra in Figure 3.8 contain a ~H80R+98 Da species. This +98 Da 
peak is present in most of our protein preparations as is thought to correspond to a sulphate 
adduct (artefact from our protein expression and purification protocol). 
 




Figure 3.8 Mass spectrum of fragmented H80R in non-reducing (A) and reducing (B) 
conditions. The H80R sample was incubated at 37 °C for 17 hours before the mass spectrum 
was obtained, at which point, an aliquot of the sample was reduced with 1% βme. Both aliquots 
were sprayed in a solution of 1:1 acetonitrile:water mixture with 0.2% formic acid. 
 
3.3.2.3 Purification of H80R  
Due to the fact that H80R is a zinc binding mutant, our initial assumption was that copper 
was undergoing non-native chemistry in the active site, resulting in the cleavage of the protein. 
Accordingly, to determine the optimal expression conditions, H80R cultures were grown in three 
conditions: without metals, with both copper and zinc and with only zinc. The protein was then 
prepared from E. coli via the regular osmotic shock protocol (Section 3.2.2.1). The three sets of 
OS were then heat treated at 50 °C, 60 °C and 70 °C with and without the addition of copper. 
This was done to determine the optimal temperature for heat treatment which should not only 
increase the purity of the OS samples but also minimize loss of H80R. Figure 3.9 shows an SDS-
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PAGE illustrating the results for the different H80R expression and heat treatment conditions. 
H80R grown with zinc had the highest yield compared to the cultures grown with both copper 
and zinc or without metals, suggesting that the addition of zinc helps stabilize H80R. Figure 3.9 
also indicates that heat treatment without the addition of copper does not significantly increase 
the purity of the OS. Samples heat treated with copper at 70 °C (Figure 3.9 Lanes 6, 13 and 19) 
have a decreased amount of H80R compared to the samples heat treated at lower temperatures, 
indicating that H80R likely aggregates at 70 °C in the presence of copper. Interestingly, reduced 
samples from all three sets of OS that were heat treated with copper (Figure 3.9 Lanes 21-23) 
contain a smaller fragment that does not show up in their unreduced counterparts (Figure 3.9 
Lanes 4, 11 and 17), further implicating copper’s role in the cleavage of H80R. In light of these 
results, H80R preparations were expressed with zinc, for higher yield, and , initially, not heat 
treated prior to purification on the hydrophobic interaction column as heat treatment without 
copper did not increase the purity of the OS. The apo H80R was made from purified as isolated 
preparations that were heat treated with copper at 55 °C. This was due to the low yields from the 
non-heated treated samples attributed to protease activity during the protein purification process 
as well as the non-ideal elution profile of non-heat treated H80R on the hydrophobic interaction 
column. All the as isolated H80R preparations were checked using SDS-PAGE with βme after 







Figure 3.9 SDS-PAGE of H80R grown and heat treated with different conditions to 
determine the most optimal set of expression parameters. H80R was grown without metals (1-6), 
with both copper and zinc (8-13) and with only zinc (14-19). The osmotic shock solutions from 
these were then heat treated with or without copper at 50 °C, 60 °C and 70 °C. Samples in lanes 
20-23 were run with 10% βme. Lanes 21-23 appear to have a low molecular weight fragment 




3.3.2.4 Preliminary results on H80R stability 
The thermal stabilities for the purified as isolated form and the apo form of H80R were 
determined using DSC. Figure 3.10 shows thermograms from two different preparations of as 
isolated H80R as well as apo preparations of H80R. The as isolated thermograms contain a large 
endothermic peak with a  of ~60 °C while the endothermic peak of the apo samples has a  
of ~59 °C. However, all the thermograms, with the exception of (d), contain a shoulder with a  
of ~74 °C. When the samples were rechecked using SDS-PAGE with βme, the samples 
contained  a small amount of fragments similar to those observed in Figure 3.7. This suggested 
that the fragmentation process was either occurring while the samples were stored at -80 °C or 
that it was a fast process occurring within the time required to prepare the samples. The shoulder 
at 74 °C is perhaps due to the unfolding of aggregates of the fragmented H80R. Despite the 
presence the fragmented species of H80R, the  of apo H80R at 59 °C indicates that it has 
comparable thermal stability to apo pWT, which has a  of ~59.1 °C (77). The lack of protein 
concentration dependence of apo H80R over a concentration range 0.76-1.43 mg/mL suggests 






Figure 3.10 DSC thermograms of as isolated (d and e) and apo (a-c) H80R. The three apo 
samples, a, b, and c, were at protein concentrations of 1.43 mg/mL, 0.97 mg/mL and 0.76 
mg/mL, respectively, while the as isolated samples, d and e, were at protein concentrations of 






3.4.1 Dimer interface mutants and G41D are destabilized compared to pWT in the 
holo state 
 The thermal stabilities of the mutants relative to pWT in the holo state were determined 
using DSC. The mutants have comparable specific activities, with the exception of G41D, to 
pWT which has a specific activity of 1800±200 U/mg (77). The dimer interface mutants A4S, 
A4T and I113T have average specific activities of 1943±63 U/mg, 1736±260 U/mg and 1668 
U/mg, respectively, while G41D has a specific activity of 1538 U/mg (± S.D. of different batches 
of protein). However, the thermogram for G41D does not appear to contain multiple peaks or 
shoulders, suggesting that the sample is homogeneous. Alanine 4 is located in β-strand I, at the 
edge of the dimer interface, and has its side chain pointing into the β barrel. On the other hand, 
isoleucine 113 is located in loop 6 and points into the dimer interface. The high specific activities 
of the dimer interface mutants are not unusual as they are located, structurally, quite far away 
from the metal binding region. It has also been found that most non-metal binding region 
mutations do not affect the activity of hSOD (19). The lower activity of G41D may be due to its 
close proximity to the MBR. Glycine 41 is located at the beginning of β-strand IV, which then 
extends to the zinc binding loop. The introduction of a charged residue at the edge of the β barrel 
could also perturb the integrity of the β barrel, which in turn would affect the structure of the 
active site. Interestingly, recent computational studies indicated that mutations located away 
from the dimer interface or MBR affect the integrity of both the dimer interface and MBR(36). 
All the mutants are destabilised relative to pWT in the holo form as reflected by their 
lower s and ∆ s. This is consistent with previous data obtained on holo hSOD mutants where 
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mutants were shown to be destabilized via thermal unfolding (28,71)((72) Chapter 4) ((73) 
Chapter 2)  as well as chemical denaturation (78)((68) Chapter 2). The lower ∆   values for the 
dimer interface mutants are due to lower ∆  which are compensated by their lower Δ  values. 
Previously studied mutants (A4V, G85R, G93A/D/R/S/V and E100G) are also enthalpically 
destabilized in the holo state (68,77). Interestingly, G41D and I113T have ΔΔ  values of 0 and 
only a small decreases in ∆  relative to pWT. Unlike the other mutants studied here, G41D is 
not a dimer interface mutant. It is located at the beginning of β-strand IV and also replaces a non-
polar residue with a charged residue. In fact, G41D is one of the few mutations in hSOD that 
increases the net negative charge of the protein as the majority of ALS-associated mutations 
decrease the net charge of hSOD (87). It is worth noting that the dimer interface mutants are 
associated with short disease durations while G41D has relatively long duration (Table 2.1) 
despite the fact that G41D has the lowest  and has comparable ∆∆  at physiological 
temperature relative to the dimer interface mutants. The long duration of G41D could be 
attributed to the increase in net charge of the protein which is predicted to decrease aggregation 
by increasing electrostatic repulsion the protein molecules (88). 
3.4.2 Dimer interface mutants have decreased dimer stability  
 Although the dimer interface mutants are well fit to the dimer 2-state model, their low /  ratios are indicative of some formation of a monomer intermediate. Due to mass 
action, the monomer intermediate would be more populated at low protein concentrations while 
the dimer would be more populated at high protein concentrations (79). This change in 
molecularity is exhibited by an increase in /  ratio towards unity with increasing 
protein concentration and can be observed for the dimer interface mutants (Table 3.1), where the 
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lower /  ratios tend to correlate with lower protein concentrations. This trend is found 
in all the holo dimer interface mutations studied in our laboratory which includes A4S, A4T, 
A4V (68) and I113T as well as non-dimer interface mutants including E100G (68), G93A and 
G93R (77). However, monomer 2-state fits for the dimer interface mutants and G41D show 
systematic deviations from the DSC thermogram similar to those observed for pWT (28), 
indicating that these mutants do not unfold in a purely monomer 2- state manner. It in worth 
noting that apo A4V and H46R have been shown to thermally unfold in a 3-state monomer 
intermediate unfolding mechanism (79). In addition, chemical denaturation studies on holo pWT, 
G85R, E100G and G93A  and apo G85R, G93R, E100G and I113T reveal that they undergo a 3-
state monomer intermediate  guanidinium chloride-induced denaturation (68,72,78). 
Additionally, isothermal titration calorimetry (ITC) on holo A4V and I113T at 65 °C 
indicated that these mutants had weaker dimer association compared pWT. ITC of holo A4V and 
I113T gave dissociation constants ( ) of 31 μM and 25μM, respectively, while holo pWT did 
not give significant heats of dissociation (quantifiable dissociation heats for the only first ~2 
injections), and therefore, a  could not be determined (77). Similarly, the G93A/D/R mutants 
did not give significant heats of dissociation. However, the G93 mutants had more injections 
with quantifiable heats of dissociation compared to pWT, indicating that they have a weaker 
dimer interface compared to pWT (77). ITC experiments conducted on apo hSOD at 37 °C also 
provide evidence for weaker dimer association in ALS-associated mutants (79). Similar to holo 
pWT, apo pWT did not give significant heats of dissociation at 37 °C while dimer interface 
mutants A4S, A4T, A4V and I113T gave s of 1.6 μM, 5.1 μM, 10.0 μM and 3.9 μM, 
respectively (79). On the other hand, non-dimer interface mutants H46R and G93S gave s of 
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0.5 μM and 1.2 μM, respectively (79). It is not surprising that apo A4V had the highest  out of 
all the mutants as DSC indicated that A4V unfolds via a monomer intermediate. This is because 
the dimer interface is sufficiently destabilized compared to monomer stability, enabling the 
detection of the two processes in DSC. On the other hand, apo H46R which also unfolds with a 
monomer intermediate had the highest measurable . This is because apo H46R has very high 
monomer stability coupled with a dimer interface that is only mildly destabilized compared to 
pWT (79), which also enables the detection of the two processes in DSC. Accordingly, the 
monomer intermediate is never significantly populated if a mutant has a strong dimer interface or 
a destabilized monomer. In light these results, it would be sensible to investigate if holo A4S, 
A4T and I113T undergo a 3-state monomer intermediate unfolding mechanism. 
3.4.3 H80R 
The presence of fragments in all the preparations of H80R regardless of the purification 
conditions is perplexing and the reason for this has yet to be resolved. It is possible that aberrant 
copper chemistry is responsible for the fragmentation of H80R. The formation of fragments after 
storage in -80 °C suggests a metal catalyzed process.  Mutant hSODs have been shown to 
participate in non-native chemistry in vitro (40,53) and although copper was not added to the 
initial as isolated preparations of H80R, the samples may contain small amounts of copper from 
the growth media. Figure 3.11 illustrates the close proximity of residues R69 and K70, the 
cleavage site, to the active site of hSOD as well as H80R, the mutation site. On the other hand, a 
study conducted by Bruns et al. indicated that H80R has decreased resistance to proteolysis (74). 
The cleave site is located in the zinc binding loop which, in the absence of zinc coordination, has 
been shown to be disordered (86). An unstructured zinc loop in the mutant may have an 




Figure 3.11 Site of cleavage in H80R. Prepared using MolMol (29) and PDB coordinates 1SOS 
(30). Each monomer contains a Zn2+ and a Cu2+ ion depicted as black and orange spheres, 
respectively. Inset is a magnification of the metal binding sites as well as the R69-K70 site where 
cleavage occurs. 
 
3.4.3 Correlations with disease  
Since the discovery of a genetic link between hSOD and ALS (21), many studies have 
been focussed on finding the common denominator of hSOD toxicity. Due to the high stability of 
the holo hSOD, including the mutants (89), many studies have suggested that the toxic form of 
hSOD is the more destabilized apo form (90) or the disulfide reduced apo form which is 
proposed to be the most immature form of hSOD in the cell (91). However, it has been found 
that destabilization of the apo protein is not a common feature for all fALS-associated mutants 
(92). A recent article by Wang et al. revealed a correlation between disease durations and the 
sum of aggregation propensity and instability of the mutants (64). The correlation, although 
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compelling, only analyzes 28 different mutants due to the limited amount of data available. 
Considering the complicated nature of ALS, it is likely that there is no common denominator and 
that the different mutants associated with ALS confer toxicity via different mechanisms, all of 
which may lead to increased population of some sort of destabilized species that has increased 





















 As in many other neurodegenerative diseases, protein aggregation is a hallmark of ALS 
pathogenesis (2). In vitro studies have shown that fALS-associated hSOD mutants have an 
increased propensity to aggregate (73,93) while x-ray diffraction and nuclear magnetic resonance 
studies have shown that the partially metallated, as well as fully metallated, S134N hSOD mutant 
tend to generate protein oligomers (94,95). More importantly, aggregates from neuronal cell line 
(13) and mice model studies of fALS (39,96,97) as well as fALS and some sALS patients have 
been found to contain hSOD (14,50,51). It is not known if the hSOD found in these aggregates 
retains their metal ions; however, given that the major species of hSOD in the cell is in the holo 
form (77), it is plausible that aggregation could occur from holo hSOD.  
Various studies on hSOD aggregation have focused on either the apo (90) or 
mismetallated forms of hSOD, or on the reduced form (91), considering holo hSOD too stable to 
give rise to aggregates in ALS (89). A recent study by Banci et al. demonstrated that disulfide 
intact apo wildtype hSOD formed aggregates at close to physiological conditions of pH 7, 37 °C 
and a protein concentration of 100 M, while both holo wildtype hSOD and holo pWT did not 
(90). The data from this study contradicts the results previously obtained by the Meiering lab 
where holo pWT as well as holo forms of fALS-associated mutants have been shown to form 
aggregates when incubated without agitation at physiologically relevant conditions of pH 7.8 and 
37 °C (77) (Y. M. Hwang unpublished data). This chapter investigates the aggregation properties 
of holo dimer interface mutants A4S and A4T and possible correlations to thermal stability and 
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disease duration. The aggregation profiles indicate that the mutants have increased aggregation 
propensities and also provide information regarding the possible aggregation mechanisms. In this 
chapter, dynamic light scattering is used to monitor aggregation of dimer interface mutants A4S 
and A4T as well as pWT in the holo state. 
4.1.2 Dynamic light scattering 
Dynamic light scattering (DLS) is one of the tools commonly used to monitor protein 
aggregation (98,99). DLS utilizes the principles of Brownian motion to measure the size of 
particles in a sample solution. A detector located at a fixed angle and distance with respect to an 
incident light beam, picks up light scattered by particles in the sample solution, which is located 
between the detector and the light source. The intensity of scattered light fluctuates about an 
average intensity and the time dependence of these fluctuations are related to the diffusion 
coefficient, , of the particles in solution (90Plus Particle Sizer Instruction Manual). The 
diffusion coefficient reflects the speed of particle movement and is inversely related to particle 
size as described in the Stokes-Einstein equation: 
      Equation 4.1  
where  is the Boltzmann constant,  is the absolute temperature,  is the viscosity of the 
sample solution and  is the diameter of the particle, which is assumed to be spherical.  
The light scattering measurement is then divided into small time intervals or delay times, 
, which are much shorter than the time required for the fluctuation to return back to the average 
scattered intensity. The autocorrelation function, ,  is a plot of the signal intensity within   
as a function of time between . With increasing delay times, the correlation between the 
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intensity products within  decreases and is eventually lost. The autocorrelation function is an 
exponential function expressed as 
    Equation 4.2 
where  is an instrument dependent optical constant,  is the autocorrelation baseline,  is the 
delay time and Γ is the decay rate constant expressed by 
 Γ  Equation 4.3  
where  is the diffusion coefficient of the particle in solution and  is the magnitude of the 
scattering vector, which depends on the instrument and sample expressed by 
       Equation 4.4 
where  is the refraction index of the sample solution,  is the wavelength of the incident light 
beam and  is the scattering angle. Because larger particles in a sample move slower through the 
sample solution, they have smaller diffusion coefficients, which results in a slower decay. Figure 
4.1 shows the autocorrelation function for a larger and a smaller particle. 
 
Figure 4.1 Autocorrelation functions of a large and small particle.  
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Dynamic light scattering can be used to monitor particle size changes over time and has 
been successfully used to monitor protein aggregation in vitro (77,100). In the case of samples 
with more than one particle size distribution, the autocorrelation function will contain 
exponentials from each particle size distribution. Algorithms such as cumulants (101) and 
CONTIN (102) deconvolute the different exponentials and provide the hydrodynamic diameter 
of the particles in solution. 
4.1.2 Nucleation-dependent protein aggregation 
Many disease-associated proteins have been shown to aggregate through a nucleation-
dependent process involving three phases: lag, growth and plateau (10,103). This process is 
associated with a sigmoidal aggregation profile (Figure 4.2) and a lag phase that is associated 
with the formation of thermodynamically unfavourable nucleus (104,105). Nucleation-dependent 
protein aggregation typically is also characterized by a protein concentration dependence of the 
lag phase whereby the lag phase shortens with an increase in protein concentration (104). 
Another feature of nucleation-dependant protein aggregation is a seeding-effect, whereby the 
addition of preformed aggregates eliminates the lag phase or nucleation step required for 
aggregate formation (10,103). Both the concentration dependence and seeding effect have been 
shown to occur in in vitro holo hSOD aggregation, indicating that holo hSOD aggregates via a 
nucleation-dependent process ((77) and Y. M. Hwang unpublished data). However, the specific 
pathways and mechanisms by which aggregation occurs are still being elucidated. In this chapter, 




Figure 4.2 A graphical representation of the sigmoidal increase in mean light scattering 










4.2.1 Expression and purification of recombinant holo hSOD 
Protein expression and purification were performed as described in Section 3.2.1 and 
3.2.2. 
4.2.2 Protein quantification and confirmation of metal status 
 Protein quantification was performed as described in Section 3.2.4. The metallation status 
and sample quality were determined by the specific activity as well as DSC as described in 
Section 3.2.5. 
4.2.3 DLS sample preparation 
 Holo hSOD aggregation protocols previously described in the thesis of Dr. Peter 
Stathopulos were used to study the fALS-associated hSOD mutant aggregation (77). Briefly, 
samples were prepared in 20 mM HEPES pH 7.8 buffer and aggregation was followed using 
light scattering as samples were incubated at 37 °C without agitation. All samples were prepared 
at a protein concentration of 10 mg/mL, unless stated otherwise, and were filtered using 20 nm 
filters (Anotop 10 Plus, Whatman) to remove any dust particles and preformed aggregates that 
may be present in the sample. Light scattering measurements were made using a 90Plus Particle 
Sizer (Brookhaven Instruments Corporation, Holtzville, NY) and a Nano-ZS Zetasizer (Malvern 
Instruments Ltd., Worcestershire, United Kingdom) in a 45 L small volume cell (Quartz 
precision cell, type 105.251-QS, Hellma GmbH and Co., Mullheim, Germany). Samples were 
gently pipetted prior to transfer into the cell and measurements were made twice a day during the 
lag phase, 3 times a day during the exponential phase and once a day during the plateau phase. 
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The aggregation profiles obtained from both instruments agree well and, to avoid redundancy, 
only aggregation time courses from the 90Plus Particle Sizer will be presented. 
4.2.4 Determining lag time from fits to a sigmoidal function 
The kinetics of holo hSOD aggregation were fit using Microcal Origin 5.0 to an empirical 
sigmoidal function given by the following equation (also shown in Figure 4.2) (105):  
     Equation 4.5 
where  is the light scattering intensity (kcps);  is time and  is the time to half completion;  
is the initial light scattering intensity;  is the final light scattering intensity; and  is the time 
constant which is the reciprocal of the apparent rate constant for the growth phase of the curve 
(1/ ). Although specific kinetic schemes cannot be obtained from the sigmoidal fit, it will 
provides a way to quantitatively compare the aggregation profiles of the different hSOD mutants. 
The lag time (duration of the lag phase) of the aggregation curve can be calculated from the 
fitted parameters using the following equation: 
 Lag time  2  Equation 4.6 
 
4.2.5 Fitting holo hSOD aggregation profiles to a primary and secondary 
nucleation function 
 Protein aggregation can occur through primary or secondary nucleation, where primary 
nucleation describes elongation occurring only at the polymer ends while secondary nucleation 
implies the formation of new polymer ends through fragmentation, branching or heterogeneous 
nucleation (104). DLS data of holo fALS-associated hSOD mutant proteins were fit to both 
primary and secondary nucleation functions to determine which nucleation pathway holo fALS-
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associated hSOD mutations undergo. Based on protein aggregation kinetics described by Ferrone 
(104), the aggregation profile for primary-nucleation will fit to a cosine function: 
 fraction of completion 1 cos  Equation 4.7 
where  is the fitted amplitude,  is the effective rate constant and  is time. On the other hand, 
the aggregation profile for secondary nucleation will fit a cosh function: 
 fraction of completion cosh B 1    Equation 4.8 
These fits are only applicable to the initial phase of the aggregation process, therefore, the 
aggregation profiles of hSOD were converted to fraction of completion and only the first 20% of 
the profiles were fit.  
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4.4 Results 
4.4.1 Holo hSOD aggregation is nucleation dependent  
 A nucleation dependent aggregation process contains a rate limiting step associated with 
the formation of a critical nucleus. This process is characterized by the lag phase in an 
aggregation profile. The addition of preformed aggregates should decrease the lag phase since 
the critical nucleus is added. Figure 4.3 shows the aggregation profiles of 3 mg/mL holo pWT 
with and without the addition of preformed seeds. The seeds were obtained from a previous 3 
mg/mL holo pWT time course with the early seeds collected at the end of the lag phase and the 
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late seeds collected at the plateau phase. The lag phase of holo pWT is reduced from 200 h to 28 
h by the addition of early seeds and completely eliminated by the addition of late seeds, 
demonstrating that holo hSOD aggregation is nucleation dependent. These results agree with and 
confirm previous results obtained for other holo hSOD variants (77) (Y.M. Hwang unpublished 
data).  
 
Figure 4.3 Nucleation dependence of holo hSOD aggregation. Aggregation profiles of 3 
mg/mL holo pWT with 5% (v/v) early seeds (triangles), 5% (v/v) late seeds (circles) and without 
seeds (squares). The dashed lines are fits to an empirical sigmoidal function (Equation 4.5). 
 
4.4.2 Dimer interface mutants A4S and A4T have shorter lag times compared to 
pWT 
The aggregation profiles of dimer interface mutants A4S and A4T as well as pWT in the 
holo state were fit to Equation 4.5 and the lag times were determined from the fitted parameters 
using Equation 4.6. Table 4.1 summarizes the lag times and fitted parameters of the holo 
aggregation profiles. Aggregation profiles with fitted initial mean light scattering intensities, , 
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that did not match experimental initial mean light scattering intensities were considered “pre-
seeded” and were not included in the lag time determination. Figure 4.4 illustrates the 
aggregation profiles for pre-seeded and a non pre-seeded (successful) holo pWT samples. The 
experimental initial mean light scattering intensities of both profiles are approximately 2.6 kcps, 
however, the fitted initial light scattering intensities of the pre-seeded and non pre-seeded time 
courses are -14.10 kcps and 2.66 kcps, respectively. The lower than expected fitted initial light 
scattering intensity as well as the absence of an appreciable lag phase indicates that the sample 
contains some preformed aggregates, perhaps as an artefact from filtering.  
 
Figure 4.4 Pre-seeded and non pre-seeded 10 mg/mL holo pWT aggregation profiles. The 
pre-seeded data points are in open circles while the non pre-seeded data points are in open 
squares. The dashed lines are fits to Equation 4.5. The initial mean light scattering intensities, , 
of the pre-seeded and non pre-seeded sample are -14.10 kcps and 2.66 kcps, respectively. 
 
Protein aggregation studies have shown that the combination of adsorption to 
hydrophobic interfaces (filter membrane or air-water interface) and the shear stress associated 
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with the filtering process could exacerbate protein unfolding (106,107), which can lead to the 
formation of aggregation nucleus. However, light scattering data from multiple holo hSOD 
samples, prepared is a consistent manner, indicate that most of the samples are not pre-seeded 
and the sample solution at the beginning of the time course as well as during the lag phase is in 
fact monodispersed. Figure 4.5 is a representative intensity plot of a holo aggregation sample 
over time. At t=0 h throughout the lag phase, the solution is monodispersed with a particle size 
of ~5 nm, consistent with the size of hSOD dimer (77). As aggregation occurs, a larger species of 
~1000nm appears.  
 
Figure 4.5 Size distribution of holo hSOD aggregation over time. (A) Aggregation profile of 
holo A4T with experimental data in solid squares and sigmoidal fit in dashed lines. (B) Intensity 
plots at different time points corresponding to points indicated in (A) for holo A4T aggregation. 
 
 Aggregation of holo hSOD samples are quite variable with varying lengths of lag times, 
growth phases and final mean light scattering intensities. This variability can be observed in 
Figure 4.6. Nevertheless, Figure 4.6 (D) and Table 4.1 show that the dimer interface mutants 
A4S and A4T appear to have shorter average lag times compared to pWT. The average lag time 
of A4T, 77.70±19.04 h, is clearly shorter than pWT, 135.28±28.48 h, while the averaged lag 
68 
 
time of A4S, 109.41±82.53 h, is slightly shorter than pWT. In Figure 4.6 (B), the aggregation 
profiles in blue and red (indicated by arrows) are from a single holo A4S sample that was split 
into two samples at the beginning of the experiment. However, they do not have similar lag times 
or final mean light scattering intensities, indicating that the variation between samples are not 
due to differences in sample quality but is intrinsic to hSOD aggregation. 
 
Figure 4.6 Aggregation profiles of holo dimer interface mutants and pWT. Experimental 
data for pWT (A), A4S (B) and A4T(C) are in hollow circles while the fits to Equation 4.5 are in 
dotted lines. (D) Bar graph of the average and standard deviation of fitted lag times reflect the 
variability in holo hSOD aggregation. A sample of holo A4S was divided into two identical 
fractions and monitored in parallel. The arrows indicate the aggregation profiles for the two holo 










intensity (kcps) a 
Final mean light 
scattering 





lag time (hrs) b
pWT 2.19±0.48 17.82±1.77 222.19±12.94 49.69±9.42 122.82±16.01 
pWT 2.68±0.29 15.73±0.86 237.90±6.74 34.78±5.26 168.34±8.55 
pWT 2.66±0.09 4.83±0.08 115.11±2.43 6.09±2.18 102.93±3.27 
pWT 2.65±0.30 7.33±0.30 155.29±3.20 4.13±4.22 147.04±5.30 
pWT -14.10±12.24 29.11±1.77 57.30±66.90 130.71±34.11 -204.12±75.10 
Mean±S.D. 135±28 
A4S 2.33±0.10 3.83±0.13 107.44±0.00 0.26±0.00 106.93±0.00 
A4S 2.37±0.23 7.84±0.20 60.07±1.26 4.09±1.27 51.89±1.79 
A4S 2.26±0.15 4.57±0.10 70.39±3.25 9.25±2.76 51.88±4.26 
A4S 2.03±0.27 10.00±0.53 405.09±21.58 89.08±20.25 226.93±29.59 
Mean±S.D. 109±82 
A4T 2.79±0.23 8.85±0.27 74.29±2.04 5.03±1.55 64.23±2.57 
A4T 2.57±0.33 11.52±0.39 105.33±8.12 7.08±4.62 91.16±9.34 
A4T -33.78±77.68 18.28±1.93 -101.11±345.25 140.31±76.10 -381.73±353.53 
Mean±S.D. 78±19 
NOTE: All samples were at a protein concentration of 10 mg/mL in 20 mM HEPES pH 7.8 and incubated at 37 °C 
without agitation. Datasets in italics are from preseeded aggregation profiles and are excluded from average lag 
time considarations. 
a Errors obtained from fitting program. 
c Errors derived using standard procedures (84) from errors in fitted  and  obtained from fitting program. 
 
4.4.3 Holo hSOD aggregation proceeds via a secondary nucleation mechanism 
 Protein aggregation can proceed via a primary or secondary nucleation process (104). 
Secondary-nucleated aggregation has a distinctively steeper initial growth phase compared to 
primary-nucleated aggregation which has a more gradual initial growth phase.  Figure 4.7 
illustrates fits to both the primary and secondary nucleation models for pWT (A), A4S (B) and 
A4T(C) and shows that pWT, A4S and A4T, like other variants of holo hSOD (77) (Y. M. 
Hwang unpublished data), fit well to the secondary-nucleation equation (Equation 4.8). The fits 
to the primary-nucleation equation (Equation 4.7) have a more gradual growth compared to the 




Figure 4.7 Holo aggregation fits to primary and secondary nucleation equations of pWT 
(A), A4S (B) and A4T (C). The solid squares are experimental data points while the dotted and 






4.5.1 Aggregates arise from holo hSOD dimer interface mutants A4S and A4T at 
physiologically relevant pH and temperature 
 A protein concentration of 10 mg/mL (317 M) was used as it is within the estimated 
range of hSOD concentration in motor neurons as well as a pragmatic solution for shortening the 
long lag times observed during holo aggregation experiments. As mentioned in Section 4.1.2, 
concentration dependence is a feature of nucleation-dependent protein aggregation, therefore, 
higher protein concentrations will result in shorter lag times. Kurobe et al. and Bowling et al. 
reported hSOD concentrations in erythrocyte lysate to be 0.95±0.07 g/mg haemoglobin and 
7.0±1.8 g/mg of protein, respectively (108,109), which correlates to hSOD concentrations of 
~10 M and 76 M, respectively (based on normal mean corpuscular haemoglobin 
concentrations of 320 g/L, also assuming haemoglobin is ~total amount of protein in RBC).  It 
has also been reported that the concentration of hSOD in brain is ~4.5 times higher than in 
erythrocytes, corresponding to hSOD concentrations of ~45-340 M (100,109). Moreover, 
immunohistochemical studies indicate that motor neurons have higher concentrations of hSOD 
compared to other neuronal populations (110). Although other studies on hSOD aggregation 
rarely have protein concentrations above 3.15 mg/mL (100 M) (90,100), there are various 
protein aggregation studies of other proteins that use protein concentrations in the range of 10 
mg/mL (111-114). 
The pWT and dimer interface mutants A4S and A4T used in the holo aggregation 
experiments were fully metallated as confirmed by the pyrogallol activity assay and DSC. The 
full metallation status of hSOD was characterized by having a specific activity of 1800±200 
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U/mg and a single endothermic peak by DSC (Figure 3.3 C and D). The correlation of this 
specific activity range to a full metallation status was previously confirmed with  inductively 
coupled plasma atomic emission spectroscopy (ICP-AES) where holo hSOD samples with 
specific activities of 1800±200 U/mg had Cu2+ and Zn2+ to monomer ratios of ~1 (77). The 
average specific activities for A4S and A4T are 1943±63 U/mg and 1736±260 U/mg, 
respectively; this, together with the single peak observed in DSC indicates that the mutants are 
fully metallated. Additionally, if aggregation occurred from a small amount of apo/mismetalated 
or misfolded protein in the sample, not only should the specific activity of the sample increase as 
aggregation occurs but aggregation should not restart after the aggregates are removed at the 
plateau phase, since both should affectively remove the apo/mismetalated/misfolded hSOD that 
may be present initially. Previous studies on holo hSOD aggregation have shown that the 
specific activity of the sample decreases with time while samples from restart experiments, 
where samples at plateau phase were filtered using 20 nm filters to remove the aggregates, go 
through another sigmoidal aggregation profile (Y. M. Hwang unpublished data). These indicate 
that the observed aggregation profiles are not due to pre-existing apo/mismetallated or midfolded 
hSOD in the sample but arise from holo hSOD. 
 Despite several studies reporting that holo hSOD does not aggregate at physiologically 
relevant conditions (37,90), we observe that holo A4S and A4T, in addition to other holo hSOD 
mutants studied in the Meiering laboratory ((77) and Y.M. Hwang unpublished data), do possess 
the ability to aggregate at physiologically relevant conditions of pH 7.8, 37 °C and without 
agitation. This discrepancy could be due to differences in experimental conditions. Thioflavin T 
(ThT) dye binding was employed in the previous studies to monitor hSOD aggregation (90,91) 
while our studies use light scattering to directly measure the change in particle size in solution.  
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ThT is an amyloid specific dye that binds to the surface of the β-rich quaternary structure of 
amyloid fibrils (115). It is worth noting that the aggregates formed in our holo aggregation 
studies as well as in ALS patients are not amyloid and do not exhibit the classical features of 
amyloid, such as long unbranched fibrils, ThT binding, in the case of our aggregates (Y. M. 
Hwang unpublished data), and green-gold birefringence when stained with Congo red, in the 
case of protein inclusions in ALS patients (11,116). It is also important to note that dye binding 
assays have an inherent shortcoming in that the addition of the dyes may affect the equilibrium 
between the various protein states in the sample (98). Another difference could be the shorter 
range of time the samples are monitored for or a lower frequency of measurements in the 
previous studies compared to the long time courses in our experiments. Identical holo hSOD 
samples, monitored concomitantly, revealed that samples that were measured more frequently 
have shorter lag times compared to those that were not (Y. M. Hwang unpublished data), 
suggesting that the sample measurement process promotes aggregation. To minimize any 
inconsistencies from the measurement process, the frequency of measurements was done in a 
consistent manner (described in Section 4.2.3) for all samples.  
4.5.2 Holo hSOD dimer interface mutants A4S and A4T have shorter lag times 
compared to pWT 
Dimer interface mutants A4S and A4T have shorter averaged lag times compared to 
pWT. This is in agreement with previous data obtained in the Meiering laboratory where dimer 
interface mutants A4V and I149T also have shorter lag times compared to pWT (77) (Y.M. 
Hwang unpublished data). However, non-dimer interface mutants G93A/D/R/S/V, with the 
exception of G85R which has an averaged lag time of ~97 h, have average lag times similar to, if 
not longer than, pWT (77,91) (Y.M. Hwang unpublished data). G85R is a mutation that disrupts 
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metal binding. This implies that a disrupted dimer interface and/or metal binding increases the 
aggregation propensity of holo hSOD and, perhaps, monomerization may be involved in 
aggregation. Monomerization is not an uncommon step in the protein aggregation pathways of 
multisubunit proteins and occurs during the aggregation of transthyretin (117) and insulin (118). 
It has also been shown that the majority of hSOD mutations either decrease dimer stability or 
increase dimer disscociation (36). In addition, studies using an antibody specific to the dimer 
interface of hSOD have shown that aggregates in mice models and in an A4V patient contain 
dimer interface exposed species (52,119). Therefore, it is reasonable to conclude that hSOD 
aggregation can proceed via monomerization or partial exposure of the dimer interface. 
The lag times also correlate with the thermodynamic stability of A4S and A4T. A4S has 
higher thermal stability compared to A4T while both mutants are destabilized compared to pWT 
(Chapter 3). Alanine 4 is located at the edge of the dimer interface and points into the core of the 
β-barrel. Both A4S and A4T replace a non-polar residue with a more polar residue and are also 
both larger compared to alanine. Both the decrease in hydrophobicity and increase in side chain 
size will likely weaken the dimer interface and destabilize the monomer. As discussed in Chapter 
3, ITC of holo hSOD mutants indicate that dimer dissociation of hSOD mutants, G93A/D/R, 
were only mildly weaker compared to pWT, while dimer interface mutants, A4V and I113T, 
much weaker with s of 48 M and 33 M, respectively (77). DSC and ITC experiments on 
apo hSOD mutants also indicate that hSOD mutants, G93S, A4V, A4S, A4T, I113T, H43R 
(arranged from high to low stability), have decreased monomer stability compared to pWT (79), 
while chemical denaturation studies on both apo and holo hSOD mutants, G85R and E100G, 
indicate that monomer stability is comparably compromised in both states (68,72,78). G85R also 
has weakened metal binding. This is interesting because G85R was the only non-dimer interface 
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mutant with an appreciably shorter lag time compared to pWT (77) (Y. M. Hwang unpublished 
data). The destabilization of the dimer interface and/or weakened metal binding combined with 
decreased monomer stability may account for the increased aggregation propensity of dimer 
interface mutants A4S, A4T, A4V and mostly likely I149T as well as G85R. The shorter lag time 
for A4T compared to A4S also agrees with patient duration data where the average duration for 
A4T is 1.5 (n=21) years while A4S is >3 (n=1) years (64). However, it is important to note that 
correlation between stability and aggregation propensity with disease duration is not well 
defined. 
4.5.3 Multiple pathways of aggregation 
It is worth noting that there is much variability in the aggregation profiles for each hSOD 
variant in terms of lag times, final mean scattering intensities and growth rates. It is generally 
accepted that protein aggregation is a complex process in which many competing reactions and 
possibly different mechanisms may occur simultaneously. It is also known that the same peptide 
or protein can form aggregates with different morphologies, possibly undergoing different 
mechanisms/pathways, depending on differences in experimental conditions and the initial state 
of the protein (98,120). An obvious possible cause and concern with regards to the variations 
observed in our studies are variations between sample preparations such as metal content or 
minor differences in protein/buffer concentrations. However, samples that have been split into 
two and measured concurrently have produced aggregation profiles that are quite different, as 
illustrated in Figure 4.6 (B). This difference in aggregation profiles of identical samples has also 
been observed in previous studies (Y. M. Hwang unpublished data), suggesting that the 
variations between samples are not due to differences in protein/sample quality but is intrinsic to 
hSOD aggregation.  
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ALS patient as well as cell model studies reveal varying fine structures of aggregates, 
from filaments of varying diameters and granule-coated fibrils to soluble aggregates (12,13). In 
addition, due to the inability to differentiate between the different secondary-nucleation 
mechanisms (fragmentation, branching, heterogeneous), we cannot preclude the possibility that 
the variations in the aggregation profiles within each hSOD variant is due to the different 
samples undergoing different combinations of aggregation pathways that lead to slightly 
different aggregate distributions, thus resulting in different aggregation rates and final mean 
intensities. Additionally, AFM of holo aggregation samples at the plateau phase do show 













Chapter 5 Summary and future work 
5.1 Production of recombinant fALS-associated mutants 
 In order to produce fALS-associated hSOD mutants in E. coli, the mutations of interest 
were introduced into the recombinant pHSOD1ASlacIq vector that encodes pWT hSOD. Using 
the pWT background allows quantitative thermodynamic analyses of the ALS-associated 
mutants to be carried out. This is due to the lack of free cysteines in the pWT construct that 
enables the reversible thermal and chemical unfolding. Seven ALS associated mutations here 
were successfully introduced the pWT background via PCR-site directed mutagenesis. Those 
mutants are dimer interface mutants, A4S, A4T, V148G and V148I, metal binding mutant H80R 
as well as charge mutants, G37R and G41D. Of these mutants, A4S and A4T were extensively 
characterized while some preliminary data was obtained for G41D and H80R. 
 The mutations H48R, N86D and I112T were not successfully introduced despite several 
attempts to do so. However, designing new primers may increase the efficiency of the PCR-site 
directed mutagenesis. I112T is a dimer interface mutation while H48R is a copper binding 
mutant. On the other, like G41D, N86D is one of the few mutations that increase the net negative 
charge of hSOD. These mutations, including the ones that were successfully obtained, are 
structurally and chemically diverse, with disease durations ranging from 0.9 years to 14.1 years 
(32,63-66). Characterization of their biophysical properties will shed more light on the 




5.2 Thermal stability of ALS-associated hSOD mutants 
 DSC was used to determine the thermal stability of dimer interface mutants A4S, A4T 
and I113T as well as G41D compared to pWT in the holo state. All 3 dimer interface mutant 
were destabilized compared to pWT, which is similar to findings for other holo hSOD mutants 
(28,71)((72) Chapter 4) ((73) Chapter 2). The mutants studied here are well fit by a dimer 2-state 
unfolding model and the dimer interface mutants exhibit protein concentration dependence 
characteristic of dimer 2-state unfolding at lower protein concentrations, with somewhat less 
stabilization than expected at increased protein concentration, perhaps due to increased 
aggregation. The dimer interface mutants had ∆ /∆  ratios of slightly less than one, which 
suggestive of formation of a monomer intermediate. Fits to a monomer 2-state unfolding model 
exhibit systematic deviations from the experimental data, as was also observed for monomer 2-
state fits of holo pWT (28); this rules out unfolding via a monomer 2-state mechanism. However, 
the low ∆ /∆  ratios in addition evidence of a monomer intermediate from ITC and 
chemical denaturation experiments of other mutants in the holo and apo states suggests that holo 
A4S, A4T and I 113T may also have a weakened dimer interface. 
 Preliminary data on H80R indicate that the mutant has comparable stability to pWT in the 
apo state. However, the as isolated H80R   of ~60 °C was only 1 °C higher than apo H80R, 
indicating that either H80R does not have any bound metals or it is only slightly stabilized by 
metal binding. All batches of purified H80R contained fragments of 7.2 kDa and 8.6 kDa in size. 
These fragments were found to correspond to the protein being cleaved between R69 and K70. 
The mechanism of cleavage is still unknown. The two most likely mechanisms are aberrant 
copper chemistry, which has been observed for mutant hSOD (40,53) or  an enhanced 
susceptibility to proteolysis. 
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5.2.1 Future work 
 All 3 dimer interface mutants have lower than predicted  at higher protein 
concentrations (Figure 3.4). However, there are very few data points at higher protein 
concentrations. To determine if the s of the mutants really fall below the predicted 
concentration dependence, more DSC scans should be performed at higher protein 
concentrations. The data should also be fit to a 3-state monomer intermediate unfolding model as 
there is precedence that the dimer interfaces of A4S, A4T and I113T are destabilized compared 
to pWT, in both the holo and the apo forms of the proteins (28,68,72,73,77-79). This will allow 
comparisons of population distribution between the mutants and pWT.  ITC experiments on the 
holo dimer interface mutants could provide more information regarding the the strength of the 
dimer interface. It has previously been shown that ITC of holo I113T at 65 °C gives heats of 
dissociation that can be used to determine the  (77).  Since I113T has comparable /
 ratios and   values to A4S and A4T in DSC in the holo form, it is likely that the s of 
holo A4S and A4T can be determined using ITC. 
  Due to the similarity in  of the as isolated and apo H80R, the metal content of this 
variant should be verified using another technique, e.g. using ICP-AES. Information from metal 
analysis could provide more insight to the mechanism of H80R fragmentation as the presence of 
copper is required for aberrant chemistry to occur. Depending on the cause of the protein 
cleavage, a modified protein purification protocol can then be developed to obtain non-cleaved 
H80R for further analysis. 
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5.3 Aggregation propensity of dimer interface mutants in the holo state 
 Holo forms of the dimer interface mutants A4S and A4T aggregate via a secondary-
nucleation mechanism. This is contradictory to studies that claim holo hSOD is too stable to 
aggregate (89). The lag times of the mutants were quantitatively determined by fitting the 
aggregation profiles to an empirical sigmoidal function. The lag times for the mutants are shorter 
than for pWT with A4T having a greater decrease in lag time compared to A4S. This correlates 
with the stability of the mutants determined using DSC where A4T is more thermally 
destabilized than A4S, while both mutants were destabilized compared to pWT. The shorter lag 
times of dimer interface mutants (A4S, A4T, A4V and I149T) compared to pWT and non-dimer 
interface mutants suggests that a weakened dimer interface increases aggregation propensity. 
However, aggregation experiments on various holo hSOD variants in the Meiering lab clearly 
indicate that aggregation can arise from this form of the protein. Also, the ability of holo pWT to 
aggregate at physiological pH and temperature and without agitation suggests a possible 
connection between fALS and sALS. 
5.3.1 Future work 
 Long term objectives of the holo aggregation studies include determining the effects of 
many different types of hSOD mutations on aggregation propensity and elucidation of the 
mechanism(s) by which aggregation occurs. An interesting avenue to pursue is the charge 
mutations such as G37R and G41D to further investigate the effects of decreasing or increasing 
the overall net charge of the protein. So far, G85R is the only mutant studied in our laboratory 
that has comparable lag times to dimer interface mutants. The other non-dimer interface mutants 
appear to have lag times similar to if not longer than pWT (Y. M. Hwang unpublished data). 
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Aggregation of holo hSOD can be compared to aggregation of other forms of hSOD as well as 
other natively folded proteins that aggregate and cause disease. This should provide valuable 
insights into fundamental aspects of aggregation mechanisms, and contribute to understanding 
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